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Abstract
The impact of opiate substitution treatment on mortality
risk in drug addicts: a natural experiment study
Colin D Steer,1* John Macleod,1 Kate Tilling,1 Aaron G Lim,1
John Marsden,2 Tim Millar,3 John Strang,2 Maggie Telfer,4
Heather Whitaker,5 Peter Vickerman1 and Matthew Hickman1
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
2National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College
London, London, UK
3Centre for Mental Health and Safety, School of Health Sciences, University of Manchester,
Manchester, UK
4Bristol Drug Project, Bristol, UK
5Department of Mathematics and Statistics, The Open University, Milton Keynes, UK
*Corresponding author Colin.Steer@bristol.ac.uk
Background: Opiate substitution treatment (OST) is the main treatment for people addicted to heroin and
other opioid drugs. However, there is limited information on how the delivery of this treatment affects
mortality risk.
Objectives: To investigate the associations of mortality risk with periods during treatment and following
cessation of treatment, medication type, co-prescription of other medication and dosing regimens during
titration and detoxification. The trends with time of prescribed medication, dose and treatment duration
were also explored.
Design: Prospective longitudinal observational study.
Setting: UK primary care between 1998 and 2014.
Participants: A total of 12,780 patients receiving methadone, buprenorphine or dihydrocodeine.
Main outcome measures: All-cause mortality relating to 657 deaths and drug-related poisoning relating
to 113 deaths.
Data sources: Clinical Practice Research Datalink with linked information on cause of death from the
Office for National Statistics.
Results: For both outcomes, the lowest mortality risk was observed after 4 weeks of treatment and the
highest risk was observed in the first 4 weeks following cessation of treatment [e.g. for drug-related
poisoning, incidence rate ratio (IRR) 8.15, 95% confidence interval (CI) 5.45 to 12.19]. There was evidence
that the treatment period risks varied with OST medication. The largest difference in risk was for the first
4 weeks of treatment for both outcomes, with patients on buprenorphine being at lower risk than those
on methadone (e.g. for drug-related poisoning, IRR 0.08, 95% CI 0.01 to 0.48). The co-prescription of
benzodiazepines was associated with linearly increasing the risk of drug-related deaths by dose (IRR 2.02,
95% CI 1.66 to 2.47), whereas z-drugs (zolpidem, zopiclone and zaleplon) were associated with increased
risk of both all-cause (IRR 1.83, 95% CI 1.59 to 2.12) and drug-related (IRR 3.31, 95% CI 2.45 to 4.47)
mortality. There was weak evidence that higher initial and final doses were associated with increased
all-cause mortality risk. In the first 4 weeks of treatment, the risk increased by 4% for each 5-mg increment
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in methadone dose (1-mg increase in buprenorphine) (hazard ratio 1.04, 95% CI 1.00 to 1.09). In the first
4 weeks after treatment ceased, a similar increment in final dose increased the risk by 3% (hazard ratio 1.03,
95% CI 0.99 to 1.07). There were too few deaths to evaluate the effects on drug-related poisoning. The
proportion of OST patients receiving buprenorphine increased between 1998 and 2006. Median treatment
duration was consistently shorter for buprenorphine than for methadone for each year studied (overall median
duration of 48 and 106 days, respectively).
Limitations: As this was an observational study, the possibility remains of bias from unmeasured factors,
which covariate adjustment and inverse probability weighting can eliminate only partially.
Conclusions: Using buprenorphine as an alternative to methadone may not reduce mortality overall
despite resulting in lower IRRs from shorter treatment duration. Clinical guidance needs to consider
strengthening warnings about the co-prescription of a range of drugs for OST patients.
Future work: Our analyses need to be replicated using other clinical data sets in the UK and in other
countries. New interventions and trials are required to investigate improving the retention of OST patients
in primary care.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Users of heroin or other opioids, such as morphine, have a risk of death 10 times higher than that ofthe general population. Overdose is the most common cause of death. In England and Wales during
2015/16, over 1200 people died from opioid poisonings, the largest number on record. The most effective
treatment for people dependent on opioids is the prescription of substitute drugs, usually methadone or
buprenorphine, called opiate substitution treatment. In the UK, this treatment is delivered commonly in
primary care, often with support from drug agency workers.
We analysed data from people on opiate substitution treatment in primary care. We assessed whether or
not death rates (all-cause and overdose) change with different periods of treatment or between treatments,
with buprenorphine compared with methadone, and with the co-prescription of other drugs such as
benzodiazepines.
Mortality risk was lowest after 4 weeks of treatment, at 0.3% for overdose deaths, but it was eight times
higher in the first 4 weeks after treatment ceased. There was evidence that mortality risk was lower for
patients on buprenorphine than for those on methadone, especially in the first 4 weeks of treatment,
when the mortality risk for the former was approximately 90% lower.
The co-prescription of benzodiazepines more than doubled overdose death rates. The co-prescription of
other drugs (zopiclone and similar sedatives, and gabapentinoids) also increased the overdose risk by 60%.
Higher doses in the first 4 weeks of treatment may be associated with higher death rates. If patients
dropped out of treatment rather than having their dose gradually lowered, this might have led to higher
death rates in the first 4 weeks after treatment ceased.
The number of buprenorphine prescriptions per year has increased over time, but treatment duration is
shorter for patients on buprenorphine than for those on methadone.
New interventions are required that retain patients on treatment in the community. Clinical guidance on
the dangers of co-prescribing drugs with opiate substitutes may need strengthening.
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Scientific summary
Background
Opioid drug misuse is a major concern in the UK, affecting up to 350,000 individuals. Opiate substitute
treatment (OST) is a common and effective treatment, with methadone and buprenorphine being the two
types of medication most often prescribed. Studies have shown an increased risk of mortality during the
first few weeks at the start of treatment and in the period immediately following cessation of treatment.
Only one study has examined how the risk profile may vary between methadone and buprenorphine, but
as that study was based in Australia it is unclear whether or not a similar pattern of risk applies in the UK.
Clinical guidelines recommend a low initial dose and then increasing the dose over the first few weeks until
a maintenance dose is achieved. Similarly, treatment should cease after a period of tapering doses, ending
with a low dose. The guidelines also advise caution when using benzodiazepines with OST patients because
of the possible drug interaction and the association of multidrug exposure with mortality.
Observational studies are prone to residual confounding related to causal factors that are omitted from
the analyses or are poorly measured. Methods such as self-controlled case series (SCCS) are robust to such
confounders, if their data do not vary with time, and may be helpful in identifying causal effects.
Objectives
This project aimed to address five main objectives associated with the five work packages:
1. To investigate the trends in the delivery of OST and how these relate to the clinical guidelines.
2. To explore factors affecting the risk of mortality, with particular reference to OST type and OST period.
3. To explore the effects of co-prescription on the risk of mortality among OST patients. Investigations
considered not only benzodiazepines but also z-drugs and gabapentinoids.
4. To explore the effects of dose regimens during induction and during detoxification on mortality risk.
Investigations considered regimens in terms of starting/ending doses and the change in dose over the
first/last 28 days of treatment.
5. To investigate how SCCS methods might be modified in the context of OST and the implications of
their results.
Methods
This study utilised data collected prospectively within UK primary care and administered by the Clinical
Practice Research Datalink (CPRD). Four main types of information were extracted:
1. Patient sociodemographic information – this included basic information such as age and gender but also
details about a patient’s history of custodial sentences, alcohol problems and overdose.
2. Medications prescribed – this information was used to identify OST patients but also co-prescribed
medications, such as benzodiazepines, that may affect mortality risk. Information on dose was
also important.
3. Practice characteristics – this included information about the practice’s location in the UK, and the
practice size in terms of the number of general practitioners and the number of OST patients.
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4. Date and cause of death – unlike date of death, cause of death was not routinely recorded within CPRD.
However, data were linked to other UK databases, allowing cause of death to be extracted from an
Office for National Statistics database. Unfortunately, at the time of this study, only about 50% of
patients had been linked, limiting the patients eligible for drug-related poisoning (DRP) analyses.
All patients were eligible for the analysis of all-cause mortality (ACM).
The identification of OST patients involved primarily those receiving at least 20 mg of methadone or 4 mg
of buprenorphine at some time. Considerable efforts were made to exclude patients receiving these
medications for pain relief. Patients receiving at least 480mg of dihydrocodeine were also included when
there was other evidence that these prescriptions were part of OST. In total, 13,005 patients were identified
between the study dates of 1 January 1998 and 31 July 2014. In mortality analyses, up to 12,118 patients
were utilised, reflecting those with ages between 15 and 64 years.
Poisson regression was the main method used to analyse mortality data. However, a variety of other
methods and weighting of the data, most notably inverse probability weighting, were employed to
obtain more robust results or were used as sensitivity analyses.
Results
The main results are listed below by objective. For objective 1, the main results on the trends in prescribing
practice were as follows.
l Patients receiving OST may have reached a peak in 2008, with current numbers about 20% lower than
at that time.
l The use of methadone within OST has been declining, whereas buprenorphine use increased up to about
2006. After this date, there was less evidence of any relative change in the use of these medications.
l The co-prescription of benzodiazepines declined during the study period while the co-prescription of
gabapentinoids increased. The co-prescription of z-drugs did not change substantially during the
study period.
l The average doses of both methadone and buprenorphine reached their maxima around 2008.
Similarly, the proportion of episodes reaching an optimal maintenance dose improved up to 2008 but
declined (methadone) or did not change (buprenorphine) after this date.
l On- and off-treatment duration generally increased during the study period. Buprenorphine had a
shorter duration for both on and off treatment.
For objective 2, the results on OST type and mortality can be summarised as follows.
l Mortality risk was lowest during treatment after the first 4 weeks. Elevated risks were observed in the
first 4 weeks of treatment and in the first 4 weeks following cessation of treatment.
l Differences between methadone and buprenorphine treatment were most pronounced in the first
4 weeks of treatment but also during the remainder of time on treatment, although the evidence was
much weaker for DRP. Here, methadone had higher risks than buprenorphine. Potentially inconsistent
results were obtained for the first 4 weeks following cessation, with ACM showing a protective effect
for buprenorphine and DRP showing no difference, although the best estimate of the difference also
showed a protective effect.
l The differences between methadone and buprenorphine for the 4 weeks after treatment had ceased
were attributed to residual confounding, despite robust methods such as inverse probability weighting
supporting this difference.
l The effect of OST type was observed to vary with age and comorbidity such that buprenorphine had
stronger protective associations among older or more comorbid patients.
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For objective 3, the main results on co-prescription and mortality were as follows.
l Co-prescription of benzodiazepines increased the risk of mortality for DRP.
l Co-prescription of z-drugs increased the risk of mortality for ACM and DRP.
l Co-prescription of gabapentinoids increased the risk of mortality for ACM, DRP and non-drug-
related deaths.
l Concurrent exposure of benzodiazepines and z-drugs increased treatment duration but did not reduce
overall ACM or DRP mortality risk.
For objective 4, the main results of the associations of initiation and cessation regimens with mortality
were as follows.
l Higher starting and ending doses were associated with increased ACM.
l Increasing the observation period from 28 days to 56 days did not change these effect sizes but
increased the weight of statistical evidence as a result of the increased number of deaths.
l There was no consistent evidence that change in dose in the first or last 28 days affected the risk
of mortality.
l There was no evidence that these effects varied with OST type.
l Too few deaths were eligible for DRP analyses to allow any reliable conclusions to be drawn.
l There was some evidence that adherence to guidelines with starting and ending doses was improving
after 2007 compared with before this date.
For objective 5, the main results from the modified SCCS methods provide some support for the
interaction between OST type and period. The Farrington method for ACM showed similar protective
effects for buprenorphine during the first 4 weeks of both the start of treatment and after the end of
treatment. However, there was no evidence of a similar beneficial effect after the first 4 weeks of
treatment. The Kuhnert method for ACM provided weak evidence of an interaction but, with the wide
confidence intervals, it was difficult to interpret. Both SCCS methods for DRP provided no evidence of an
interaction but the wide confidence intervals may suggest that these analyses were underpowered.
Conclusions
Our findings provided a conflicting picture of overall mortality rates related to methadone and
buprenorphine treatments. Although analyses of mortality data suggested a beneficial effect for
buprenorphine and suggested advantages to prescribing buprenorphine, especially during induction,
simulations based on DRP mortality rates under a scenario of induction with buprenorphine with
methadone thereafter were more equivocal on the net effect.
All-cause mortality rates increased after the cessation of treatment. This may be the result of poor retention
during detoxification in the final stages of treatment or poor coping mechanisms following the planned
cessation of treatment. Both are likely to benefit from greater patient support.
Our data suggested that the co-prescription of benzodiazepines and z-drugs had a detrimental association
with mortality. Although recent guidelines suggest caution in prescribing OST to patients with benzodiazepine
dependence, this study suggests that the warnings should be extended to prescribing benzodiazepines and
z-drugs to patients undergoing OST.
There was evidence that adherence to clinical guidelines on dosing, in particular low starting and ending
doses, may help to reduce mortality. The results for change in dose based on a 28-day window were
equivocal, but this may have reflected too short a period in which to assess changes in dose.
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Our study was limited by the availability of data on the addiction severity, the quality of OST (e.g. the use
of supervised consumption) and the extent of psychosocial support. It is possible that such factors may
have confounded our results.
Further work is needed to replicate our findings. In particular, such studies could clarify the role of
gabapentinoids on mortality risk and whether older or more comorbid patients benefit from buprenorphine
treatment more than from methadone treatment. Larger population-based data sets or more specialised
data sets on addiction may help to identify the role of initiation and cessation dosing regimens on
drug-related mortality, which our study was underpowered to evaluate.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Context
Background
Opiate substitution treatment (OST) is the key treatment for heroin dependence and has been shown to have
multiple benefits, including reducing drug-related crime and blood-borne virus transmission and improving
social functioning, as well as reducing drug-related deaths.1–5 Prescribed OST in the community includes
primarily methadone but also buprenorphine and occasionally dihydrocodeine.1,6 Clinical guidance advises
that the choice of drug should take account of a number of factors, including retention and treatment
compliance, the patient’s preference and the clinician’s experience with prescribing these drugs.7,8 When the
choice is unclear, methadone should be prescribed as the first choice.8 In England there are approximately
350,000 opioid-dependent people and 150,000 people who inject drugs, although these estimates are
uncertain as they can vary substantially by method of derivation and by source of information.9–12 Of these
people, about half are exposed to drug treatment annually, mainly OST (75%) but also non-pharmacological
treatments delivered in specialist drug agencies and residential units.9 OST is effective because it reduces illicit
opioid drug consumption, in particular drugs used through injections, and is cost-effective because of the
subsequent reductions in drug-related crime and health harms.13 Observational studies14–18 have shown that
the risk of mortality is reduced during OST. Buprenorphine, hypothetically, is less likely than methadone19
to cause fatal overdose, and in some studies it has been shown to be as good as methadone at treatment
retention,20 although in others the dropout rates were higher.16,21–23 In France, ecological analyses suggest
that trends in overdose deaths are negatively associated with increases in buprenorphine prescription.24
However, there is little direct comparative evidence on the risk of death during buprenorphine versus
methadone treatment, and none in the UK.
Several recent studies15–17,25 have highlighted that there is a period of very high mortality risk in the first few
months immediately after treatment cessation, which is at least eight times higher than the mortality risk
during treatment. In the UK, analyses of primary care information have suggested that the risk of death in
those who receive OST is twice as high among men as among women, is raised at the beginning and end
of treatment, and may be higher in those co-prescribed benzodiazepines.15,26 In Australia, the risk of death
at treatment onset was greater than in the UK, with some evidence to suggest that the mortality risk at
treatment onset was lower among those initiated on to buprenorphine than those initiated on to methadone,
but these benefits may be offset by a shorter duration of treatment for those on buprenorphine than for
those on methadone.16 The evidence base for other drug treatments (residential rehabilitation, detoxification,
and psychological treatments) is more limited, but studies also suggest that the risk of mortality is reduced
during treatment compared with out of treatment, and is elevated within the first 30 days compared with
> 30 days after treatment ceases.17,27
The effect of prescribing other medications to OST patients has also been studied. Research to date has
focused on benzodiazepines, z-drugs (zolpidem, zopiclone and zaleplon) and gabapentinoids (gabapentin
and pregabalin). Here, studies26,28–33 have suggested that the prescription of these medications may increase
the risk of mortality. Despite this, and against treatment guidelines,34,35 many OST patients are prescribed
these medications.28,29
Other aspects of treatment may also be important, such as additional psychological support, supervised
consumption, titration up and tapering down of OST doses at the beginning and end of treatment, and
take-home naloxone.35 Clinical guidance recommends that, at the initiation of OST, patients are started
on low levels of methadone or buprenorphine and then steadily increased to achieve an optimum level of
prescription while minimising the risk of overdose.7,36 The planned discharge of patients should involve
gradually tapering doses to low levels while minimising withdrawal symptoms. Supervised consumption,
at least initially, also is recommended to ensure compliance and reduce diversion.
DOI: 10.3310/hsdr07030 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 3
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Steer et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
In the UK, OST has expanded fivefold in the past 10 years to > 1800 kg per year (≈33.3 million doses per
year).37 The rate of methadone deaths per gram of methadone prescribed has fallen, coinciding with and
attributed to the issuing and implementation of clinical guidelines recommending greater supervised
consumption;38 however, the overall number of opiate-related deaths has not declined.39,40
Need for further research
The management and expectations of drug treatment are evolving, with the current drug strategy and
treatment guidance focusing on steps to improve ‘recovery’.41 Evidence, however, on the impact of
different ways of delivering treatment on drug-related mortality is limited,40 and this is essential for current
and future policy. It is not the intention of current treatment guidelines to reduce patients’ access to, or
limit the duration of, OST. Indeed, the latest guidance emphasises that ‘it is not acceptable to leave people
on OST without actively supporting their recovery and regularly reviewing the benefits of their treatment
. . . Nor is it acceptable to impose time limits on their treatment that take no account of individual history,
needs and circumstances, or the benefits of continued treatment’.41 Many of the sentiments expressed in
this document are echoed in the latest Home Office guidelines.42 Nonetheless, user groups do fear that a
reduction in treatment duration may be a consequence of the promotion of recovery in some local areas.
Clinical guidance also has been reissued since this study was completed, emphasising the importance of
adjunct therapies (psychosocial support) to retain people in OST, prevent chaotic dropout and achieve
multiple benefits of OST.43 In addition, the guidance supports ‘a more explicit focus on individually defined
recovery journeys with an enhanced focus on keyworking and care planning that integrates support for
pharmacological and psychosocial interventions, and peer engagement and mutual aid’. OST is primarily
delivered in the community through primary care, often in shared care arrangements with drug agencies or
solely in the care of community drug agencies.30,44 Earlier studies have examined mortality risk in and out
of treatment utilising routine data collected from community drug agencies [National Drug Treatment
Monitoring System (NDTMS)].30 However, NDTMS data may not record accurately the start and end of OST
and historically NDTMS does not collect data on the dose or type of OST. In this study, therefore, we used
Clinical Practice Research Datalink (CPRD) data to examine the mortality risk of patients with an opioid
disorder in primary care.
Large-scale observational studies, combined with mathematical modelling, are the most feasible approach
by which to address questions about mortality risk. Published trials of OST are underpowered and rarely
measure mortality risk, making synthesis of their findings unlikely to be informative.5 There are few large-scale
existing observational cohorts that reliably and adequately measure the relevant outcomes and exposures18
and no large-scale ‘head-to-head’ comparisons of buprenorphine versus methadone treatment. In previous
studies in the UK, there was insufficient power to detect differences in the risk of death for patients on
methadone or buprenorphine, and information on specific causes of death was unavailable, prohibiting the
investigation of drug-related deaths.15,26 In addition, the exposure (and the effect) of the co-prescription of
benzodiazepines or other drugs was examined in only one study in Scotland.26 Careful consideration of
confounders in the analysis of observational cohorts, however, will be important. One of the key analyses is
to compare mortality risk between people prescribed buprenorphine or methadone (i.e. OST modality), and it
is likely that the characteristics of opiate users prescribed buprenorphine or methadone will differ, which may
be lost in simple comparisons of the risk of death by OST modality exposure.45 Propensity score methods may
be helpful in providing a more robust comparison of modality than simple covariate adjustment.46,47 More
recently, self-controlled case series (SCCS) methods have been developed, which may also be helpful in
addressing these issues of residual confounding.48–50
Thus, previous analyses need to be expanded to assess the effect of OST on drug-related poisoning (DRP)
(as well as overall mortality), to assess how changing the delivery of treatment may influence the risk of
death, and to use different methods to test and address issues of confounding.
CONTEXT
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Chapter 2 Aims and objectives
Our overarching hypotheses are that the impact of OST in reducing deaths from DRP is influencedby modifiable treatment-related factors (such as treatment duration, co-prescription of other drugs,
treatment modality and dose, and dispensing arrangements). In addition, the benefits of OST in reducing
drug-related deaths in the population may be outweighed or balanced out by other factors that increase
the risk of mortality for subgroups of opioid users or for other aspects of treatment.
The aim of the study, therefore, is to add to the body of robust evidence concerning treatment-related
factors to inform and improve treatment guidelines that can underpin the effective reduction of population
drug-related deaths through primary-care-based intervention. This project will focus on the analysis of OST
delivered in primary care using the analysis data from the CPRD.
Our main research questions and goals to be addressed include:
l Is there evidence that the delivery of OST in primary care has changed over time – specifically in terms
of changes in average dose and percentages of patients receiving optimal OST dose; OST modality;
number and percentages of patients undergoing a planned discharged over time; number and
percentages of patients receiving co-prescription of benzodiazepines; and number and percentages of
patients with evidence of supervised consumption? [work package (WP) 1]
l We shall determine the risk of overdose and death by treatment exposure and modality, relate these
effects to the number of overdose deaths and coverage and duration of drug treatment in the community,
and project what factors could reduce the number of drug-related deaths in the population. (WP 2)
l Does any difference in the risk of mortality between prescribed methadone or buprenorphine change
with the period of treatment exposure? (WP 2)
l Is the risk of mortality increased in people who are co-prescribed benzodiazepines, z-drugs or
gabapentinoids (pregabalin and gabapentin)? (WP 3)
l Is the risk of death at treatment onset and cessation reduced in patients with evidence of supervised
consumption and planned discharge? (WP 4)
l Adapt the SCCS methodology, originally developed for assessing vaccinations on health outcomes,
for use in medication-based treatment. (WP 5)
Work packages 1–5 are reported in Chapters 4–8, respectively.
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Chapter 3 Methodology
This chapter describes all aspects of study design, data collection and data analysis.
Conceptual framework of study
Natural experiments or observational studies provide opportunities to study interventions for which ethical
considerations may prevent a controlled experiment such as a randomised controlled trial.45 Publicly
accessible databases, such as CPRD,51 provide a cost-effective strategy for investigating interventions in a
UK-representative sample. However, the lack of control in the study design can introduce bias into the
results, and care is needed when analysing these data.45
Clinical Practice Research Datalink
The CPRD is a large database of anonymised patient records from 674 general practices and > 11 million
patients in UK, covering 7% of the UK population at the time of this study. It is broadly representative of
the UK in terms of sociodemographic characteristics and has good validity and replicability in relation to
chronic illness.52
The Clinical Practice Research Datalink can provide information on the patient (gender, year of birth,
registration and transfer out dates with the primary care practice, and date of death if applicable), their
history of prescriptions (including daily dose and duration), entries in the clinical notes (including information
on comorbid conditions and psychosocial adversity), the prescribing general practitioner (GP) (via anonymous
identifier) and the primary care practice (region, date after which data are considered up to standard, and
last data collection date by CPRD).51
Study design
This study was a prospective observation study using CPRD. Data were extracted on patients prescribed
methadone or buprenorphine in primary care between 1 January 1998 and 31 July 2014. These data were
expanded to include patients prescribed dihydrocodeine when the clinical notes indicated evidence of substance
abuse. Patients were eligible for inclusion in the study if they were aged 15–64 years at entry. Patients were
followed up from the latest of the study start date, the patient registration date or the up-to-standard date.
Follow-up ended at the earliest of the study end date, the last data collection date, the transfer out date, the
date of death or 1 year after the last OST ended. OST patients were defined as having been prescribed a daily
dose of at least 20 mg of methadone, 4 mg of buprenorphine or 480 mg of dihydrocodeine.
Participants
The data extracted consisted of all patients prescribed methadone or buprenorphine between the study
dates with additional patients prescribed dihydrocodeine when there was some evidence of drug abuse
from the clinical notes. Thus, the initial data set consisted of 50,151 patients, of whom 49,729 were
prescribed methadone or buprenorphine at some time during the study. It was recognised that a large
proportion of these were receiving treatment for pain relief. To remedy this, patient histories excluded any
prescriptions on which the prescription text contained ‘pain’ (mainly affecting dihydrocodeine), where the
form of medication was patches (exclusively affecting buprenorphine) or when the prescription preceded
the start of OST (exclusively affecting dihydrocodeine). This led to 53% of the patients being excluded
(Figure 1). With 20% excluded on dose criteria, the final number of valid patients was 13,005 (26%).
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The number of patients varied between the WPs. The various exclusion criteria and the data relevant to
each WP are shown in Figure 2.
Prescription daily doses, prescription duration and treatment episodes
Information on total quantity was present for 99.9% of prescriptions, reducing to 28% for daily doses and
9.1% for duration. Overall, complete information was available for only 2.2% of prescriptions, a further
32% having two items from which the third could be derived. To estimate the missing information for
the remaining 66%, prescription patterns (such as other proximal prescriptions of the same quantity or
trends in dosage history) were used to estimate daily dose, or prescription intervals were used to estimate
prescription duration.
Opiate substitution treatment episodes were derived from patient histories when a gap of > 28 days
existed between the expected completion of one prescription and the start of the next (all WPs). The CPRD
sequence number, intended to indicate repeat prescriptions within a treatment episode, was set for only
50% of prescriptions in these data. Having derived treatment episodes, OST periods could be defined
for each patient history. Four categories, as used in other studies,15,53 were defined: the first 4 weeks of
treatment, the remainder of any time on treatment, the first 4 weeks following cessation of treatment and
any remainder of time off treatment.
Ever prescribed methadone/buprenorphine
(Data set: episodes; patients; deaths)
• All cause: n = 248,179, n = 49,279, n = 4506
• Drug related: n = 134,168, n = 26,258, n = 494
• Other causes: n = 146,407, n = 28,684, n = 2920
• All cause: n = 77,415, n = 22,955, n = 2094
• Drug related: n = 44,615, n = 12,713, n = 418
• Other causes: n = 47,886, n = 13,639, n = 1344
• All cause: n = 42,533, n = 13,005, n = 975
• Drug related: n = 24,866, n = 7027, n = 338
• Other causes: n = 25,914, n = 7254, n = 565
• All cause: n = 36,607, n = 13,005, n = 736
• Drug related: n = 21,624, n = 7027, n = 127
• Other causes: n = 22,359, n = 7254, n = 319
Pain relief
Prescriptions were excluded when there was
evidence of treatment for pain relief
• All cause: n = 170,764, n = 26,324, n = 2412
• Drug related: n = 89,553, n = 13,545, n = 76
• Other causes: n = 98,521, n = 15,045, n = 1576
Maximum dose too low
Patients were excluded when their maximum
daily dose across all their episodes was < 20 mg 
of methadone or < 4 mg of buprenorphine
• All cause: n = 34,882, n = 9950, n = 1119
• Drug related: n = 19,749, n = 5686, n = 80
• Other causes: n = 21,972, n = 6385, n = 779
Outside patient follow-up period
Episodes outside this period were excluded
• All cause: n = 5926, n = 0, n = 239
• Drug related: n = 3242, n = 0, n = 211
• Other causes: n = 3555, n = 0, n = 246
FIGURE 1 Flow chart of patients, episodes and deaths included in this study. This figure shows the numbers of
episodes, patients and deaths for the all-cause, drug-related and other, non-drug-related, data sets. Prescriptions
for pain relief were identified based on prescription text, medication in the form of patches or episodes of
dihydrocodeine prior to starting OST. The follow-up period varied by patient and reflected a combination of the
study period (January 1998 to July 2014), the patient registration period with the primary care practice, the CPRD
usable data date and 1 year after the last treatment ended.
METHODOLOGY
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OST data
(Data set: episodes; patients; deaths)
• All cause: n = 36,607, n = 13,005, n = 736
• Drug related: n = 21,624, n = 7027, n = 127
• Other causes: n = 22,359, n = 7254, n = 319
• All cause: n = 35,118, n = 12,171, n = 725
• Drug related: n = 20,773, n = 6580, n = 125
• Other causes: n = 21,512, n = 6809, n = 315
• All cause: n = 34,521, n = 12,171, n = 725
• Drug related: n = 20,464, n = 6580, n = 125
• Other causes: n = 21,192, n = 6809, n = 315
• All cause: n = 29,540, n = 12,118, n = 657
• Drug related: n = 17,456, n = 6555, n = 113
• Other causes: n = 18,041, n = 6777, n = 285
Analysis of co-prescription (WP 3)
Analysis of OST type (WP 2, WP 5)
• All cause: n = 26,546, n = 11,033, n = 587
• Drug related: n = 15,600, n = 5935, n = 87
Incomplete episodes
Exclude episodes starting before or ending
after patient follow-up dates
• All cause: n = 5347, n = 225, n/a
• All cause: n = 31,260, n = 12,780, n/a
Analysis of trends (WP 1)
Outside age range (15–64 years)
Older and younger patients were excluded
• All cause: n = 1489, n = 834, n = 11
• Drug related: n = 851, n = 447, n = 2
• Other causes: n = 847, n = 445, n = 4
Immortal time periods
Periods after 1 year since treatment ended
for any episode were excluded from analysis
• All cause: n = 597, n = 0, n = 0
• Drug related: n = 309, n = 0, n = 0
• Other causes: n = 320, n = 0, n = 0
• All cause: n = 4981, n = 53, n = 68
• Drug related: n = 3008, n = 25, n = 12
• Other causes: n = 3151, n = 32, n = 30
• All cause: n = 2907, n = 802, n = 460
• Drug related: n = 1582, n = 390, n = 81
• All cause: n = 26,544, n = 11,289, n = 123
• Drug related: n = 15,822, n = 6151, n = 20
• All cause: n = 2994, n = 1085, n = 70
• Drug related: n = 2441, n = 842, n = 26
Not solely M or B
Periods involving multiple medications or
dihydrocodeine were excluded
Not solely M or B during first/last 28 days
Not solely M or B during a single episode
Initiation and cessation (WP 4)
FIGURE 2 Relationship between the WPs in this study. B, buprenorphine; M, methadone; n/a, not applicable.
WP 1 comprised the most data of all WPs, primarily because of the inclusion of dihydrocodeine episodes. Mortality
was not analysed in this WP. The numbers quoted reflect minima used in the analyses of optimal doses. Other
outcomes, such as the prevalence of OST, used the full OST data set. Other WPs restricted data to methadone and
buprenorphine only, with WP 3 using the most data (any periods relating to these medications) and WP 2 using
the fewest data (episodes of only one medication). The exclusion of periods > 1 year after the cessation of
treatment for each episode (immortal time bias) affected the person-years at risk but not the number of deaths.
The numbers for WP 4 reflect the combined total of all analyses, although in practice initiation and cessation used
different data sets. Deaths relating to other non-drug-related causes were analysed in WP 3 only.
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Episodes for benzodiazepines and z-drugs were generated in a similar fashion, but the gap between
treatments was reduced to > 14 days to reflect the shorter expected treatment duration for these
medications (WPs 1 and 3). Episodes for gabapentinoids were generated using > 28 days.
Main outcomes
The main outcome was date of death. For all-cause mortality (ACM), the date of death was obtained from
CPRD. This was, to some extent, a derived variable extracted from various sources with varying degrees of
accuracy. The most accurate was the death administration database, followed by statements of death as
recorded in the clinical notes and, finally, the least accurate was the transfer out date with the reason
given as death. CPRD has developed an algorithm for reconciling these sources of information.
Cause-specific mortality could be identified only for those patients linked to death certificate data supplied
by the Office for National Statistics. Deaths from DRP were identified from the International Classification
of Diseases, Ninth Edition (ICD-9) and International Classification of Diseases, Tenth Edition (ICD-10)
codes.54 These codes were supplemented to include more general, non-specific causes to reflect the
potential under-reporting of DRP. The list of relevant codes is given in Appendix 1. The remainder of the
deaths were classified as other, non-drug related deaths. No information on cause of death was available
for patients from Scotland, Wales or Northern Ireland.
Main predictors
Opiate substitution treatment medication, particularly methadone and buprenorphine, and OST period
were studied in WP 2. The period was defined to cover both periods of treatment (the first 4 weeks and
the remainder of the time until cessation of treatment) and subsequent periods following the cessation
of treatment (the first 4 weeks and the remainder of time until the next episode). This data set was also
used in WP 5, where the modified SCCS methods were applied. The co-prescriptions of benzodiazepines,
z-drugs and gabapentinoids were the main predictors in WP 3. Initiation and cessation doses were studied
in WP 4, while year (1998 to 2014) was the main predictor in WP 1. Further details can be found in the
specific chapters relating to each WP.
In WP 1, the main predictors and patient characteristics used in other WPs became outcomes in this WP as
their trends across time were explored.
Main confounders
The main adjustment variables were age, gender, calendar year, comorbidity score and UK region.15,16,26,55
Other potential confounders such as social class,26,55 last treatment dose15,55 or episode number15 were
omitted because of lack of any consistent evidence of an effect from these studies.
The comorbidity score was derived from 17 chronic illnesses.56 A list of 3156 Read codes had been linked
to these illnesses. These were translated to the current CPRD medcodes. This was possible for 2856 codes.
A time-varying covariate was calculated based on information on the earliest onset of these illnesses and
the weight given to each. The comorbidity score was derived by accumulating the weights across time for
each patient. Although the score had a range of 0–11, in analyses, this variable was recoded to 0, 1 or ≥ 2.
In WP 3, OST type and period were used as additional adjustment variables.
METHODOLOGY
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Propensity scores
In WPs 2 and 3, propensity scores were generated for prescribed medications using logistic regression on
four groups of variables.
1. Other prescribed medications. Propensity scores were generated for buprenorphine compared with
methadone, and benzodiazepines, z-drugs and gabapentinoids compared with non-prescription.
For each medication’s propensity score, the other three medications were used as predictors. As
buprenorphine was an alternative to methadone, its propensity score could be generated for each
episode. For other medications, propensity scores reflected whether or not they were ever exposed
during each patient’s history of prescriptions.
2. Practice characteristics. General practices were described by the number of OST patients receiving
treatment during each year of the study, the size of the practice and the UK region. The size of practice
was defined by the number of GPs writing prescriptions, OST or other, in any one year, excluding those
identified as locums. UK region was used in all analyses, and the other two measures were used solely
in propensity score derivation.
3. Psychosocial adversity. Five measures of adversity were derived from the recording of relevant CPRD
medcodes in the clinical notes (see Appendix 2). These data were used to generate non-time-varying
binary variables reflecting any recoded event of self-harm, having ever taken an overdose, having ever
had alcohol problems, having ever been in prison or having ever been homeless.
4. Main confounders. The five main confounders noted above were also included in the model.
These scores were used in inverse probability weighted (IPW) or propensity score matching (PSM) analyses.
Public and patient involvement
Interviews in small groups were conducted by two facilitators from the Bristol Drugs Project during
2015–16. These occurred in two geographical sites and involved multiple services (see Appendix 3). Focus
groups with staff and service users explored their views and preferences around substitution therapy with
methadone compared with buprenorphine and around considerations influencing their concurrent use
of benzodiazepines, z-drugs and gabapentinoids. Service users were also asked for their views on the
research questions we considered in this project in terms of the relevance of the questions, the priority
they would attach to them and any additional questions that they felt were important. Where feasible,
we used these views to inform our analysis plan.
Statistical analyses
Mortality data were analysed using Poisson regression (WPs 2 and 3). In WP 5, fixed-effect Poisson
regression clustering on patients was used to analyse mortality data as part of SCCS analyses. The results of
these analyses are reported as incidence rate ratios (IRRs). Mortality was also analysed using survival analysis
(WPs 2–4). For these analyses, the risk of mortality was reported as hazard ratios (HRs). In unadjusted
analyses for WPs 2–4, mortality rates are also reported. For WP 1, linear and logistic regression were utilised
depending on the outcome. Further details can be found in Chapter 4.
A number of techniques were utilised in an attempt to provide estimates less susceptible to bias from
residual confounding than those from standard adjusted Poisson analyses. The primary technique was IPW
used in WPs 2 and 3. Simply, this method aims to emulate a randomised trial by utilising weights reflecting
the inverse probability of receiving the observed treatment.47 This has the effect of evenly distributing
confounders between the exposure groups. PSM also attempts to balance confounders between the
exposure groups, but here the balancing is achieved more directly by choosing observations from the
two groups with similar propensity scores. In WP 2, PSM was applied to episodes of either methadone or
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buprenorphine. Matching was achieved if the two episodes had their logits of the propensity score within
0.25 standard deviation (SD).46 The third method was instrumental variables (IVs).57 A valid IV is causally
related to the exposure, related to the outcome only via the exposure and unrelated to confounders.
Previous studies have utilised physicians’ prescribing preference as an IV.58,59 In WP 2, the prescribing GP’s
previous OST prescription was explored as an IV.
In WP 4, initiation and cessation dose characteristics were estimated for the first/last 28 days of each
episode. Because death may have occurred during these periods, linear growth models were used to
estimate the latent trajectories.60
On a technical point, it is worth commenting on the relationship between unadjusted mortality rates,
IRRs and HRs. For standard Poisson regression, IRRs are identical to the equivalent mortality rate ratio, but
for other analyses, this equality does not hold. Hence, Poisson regression clustering on patient will always
adjust for patient differences. Similarly, in survival analysis, effects are always estimated relative to the
survival function, which is usually related to age. Hence, although we refer to unadjusted analyses, models
involving a single factor or covariate, it is important to recognise the implicit adjustment being made in
some of these analyses.
Effect of opiate substitution treatment on drug-related poisoning
mortality in the population
In WP 2, we estimated the probability that OST reduces DRP in the population by calculating weighted
mortality risk ratios of DRP deaths. These mortality ratios compare the observed mortality risk in patients
undergoing OST with the assumed mortality risk of opioid-dependent patients who do not enter OST
(accounting for fluctuating mortality risk in different periods on and off OST, and for variation in the duration
of current treatment). We also estimated the minimum duration of methadone and buprenorphine required
to reduce DRP deaths in the population (for more details see web appendix 2 in that WP’s main report61).
Research ethics approval
Ethics approval for this research project was obtained from Independent Scientific Advisory Committee,
Medicines and Healthcare products Regulatory Agency (protocol 14–0732R2Mn2).
Reporting guidelines
This report follows RECORD (REporting of studies Conducted using Observational Routinely-collected
health Data) guidelines for the reporting of observational studies.62
METHODOLOGY
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Chapter 4 Trends in opiate substitution treatment,
patient characteristics and prescribing practice
Deaths from DRP were 50% higher in 2014 than in 1998.54 This may suggest that there were majorchanges in the characteristics of those who abuse drugs and their treatment during this period. In this
chapter on WP 1, we explore some of these changes.
Aims and objectives
In this WP, we aim to investigate how OST delivery has changed over time, in terms of:
l number of OST patients and episodes by OST type
l patient characteristics such as age, gender and medication prescribed
l episode characteristics such as mean and maximum dose and duration.
Details of the starting and ending doses are considered in Chapter 7.
Data set
The data used in these analyses were restricted to episodes in which some part of treatment occurred during
the study period. To obtain a more accurate picture of the trends in these data, we considered all episodes
including those involving dihydrocodeine or more than one medication and all patients ignoring the age
restriction used in other WPs (see Figure 2). This led to the data for 12,780 patients and 34,427 episodes
being analysed.
Prevalence of opiate substitution treatment
Crude UK prevalence estimates were derived from valid OST patients within each year and the total
number of patients within CPRD. To obtain adjusted prevalence estimates, it was necessary to estimate the
number of OST patients for the UK. This was achieved by combining numbers of patients for each country,
taking into account the different coverages for each country by CPRD.
Patient characteristics
These outcomes include age and gender demographics and the medications prescribed. Medications
included not only the three OST medications but also benzodiazepines, z-drugs and gabapentinoids.
The last three medications were considered to be prescribed only during valid periods for each patient.
Episode characteristics
Mean and maximum doses were considered as outcomes. These are reported by year for episodes
involving only methadone or buprenorphine. Average doses were calculated daily for the parts of episodes
within any given year. Maximum doses were reported as a percentage of episodes with ≥ 60 mg for
methadone or ≥ 12 mg for buprenorphine. The last episode for each patient was excluded if treatment
was ongoing at the time follow-up ceased. This reduced the episode count to 31,260. For this outcome,
episodes were valid only for the year associated with the maximum dose.
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In addition, on- and off-treatment duration were investigated. Episode treatment was considered to cease
when there was a gap of > 28 days between the end of one prescription and the start of the next. Last
episodes were right-censored by the death of the patient, the last CPRD data collection date or the end of
the study. First episodes were potentially left-censored by the practice up-to-standard date, the start of
patient follow-up (registration with a CPRD practice) or the study start date.
Statistical analysis
A number of different analyses were used to assess trends depending on the particular outcomes. The
prevalence of OST was analysed using Poisson regression. Binary outcomes (gender, medications and dose
criteria) were analysed using logistic regression. Trends in duration were analysed using survival analysis to
take account of censoring. Different parametric distributions were compared to find the best fit (Table 1).
These analyses suggested that the log-normal distribution was superior, although other distributions gave
similar results. Other outcomes, namely age and mean dose, were analysed using linear regression.
Primary analyses involved unadjusted year effects. Trends were assessed in two ways. First, a linear
year effect was fitted to the data. Second, a deviation statistic was calculated. This reflected twice the
difference in log-likelihoods between a model treating year as a factor and the linear model. The derived
statistic [15 degrees of freedom (df)] provided evidence of any non-linearity. Where the analysis involved
linear regression, the trend is additive from one year to the next. For other analyses, there is an implicit log
transformation making the trend a multiplicative effect from one year to the next when back transformed.
Trends in prevalence of opiate substitution treatment
Most countries in the UK showed similar trends in that OST prevalence rates and number of patients
were increasing at the start of the study and declining by the end (Table 2 and Figure 3), although for
Northern Ireland, where the use of primary care to treat problem drug use is more limited, these data were
underpowered to detect the possible inverted U-shaped trend. The observed maxima varied by country and
ranged between 2008 and 2011 for three nations, with Scotland showing an earlier peak, in 2003. Overall,
the UK showed a maximum in 2008. Perhaps as expected, the adjusted UK estimates were similar to the
unadjusted estimates because of the major contribution of England to the UK total.
TABLE 1 Comparisons of parametric survival functions for the analysis of duration
Function
Duration model log-likelihood
On treatment Off treatment
Gompertz –52,482 –34,247
Log-logistic –49,384 –33,199
Generalised gamma –48,827 a
Exponential –57,672 –35,245
Weibull –50,558 –34,372
Log-normal –48,900 –32,415
a This model failed to converge.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
TABLE 2 Prevalence of OST by country and year
Year
CPRD coverage by country (%) Prevalence by countrya UK adjusted
England Wales Scotland Northern Ireland UK England Wales Scotland Northern Ireland UK Prevalencea nb
1998 4.61 6.36 3.19 4.71 4.57 4.04 1.94 12.34 0.96 4.32 4.58 28
1999 5.70 8.35 3.87 5.57 5.66 4.72 3.17 11.96 1.32 4.94 5.18 32
2000 6.40 10.01 4.52 6.97 6.43 4.86 3.32 12.75 1.13 5.11 5.36 33
2001 7.00 11.41 5.85 7.87 7.15 4.89 3.23 14.53 1.22 5.33 5.54 34
2002 7.45 11.63 7.13 8.82 7.66 5.24 3.96 15.60 1.15 5.84 5.96 37
2003 7.45 12.48 9.05 8.85 7.87 5.61 4.93 17.11 1.01 6.53 6.42 40
2004 7.68 13.06 9.46 9.21 8.14 6.05 5.36 16.87 1.15 6.91 6.80 43
2005 7.75 13.34 9.54 9.24 8.22 6.65 5.94 17.02 1.45 7.46 7.35 46
2006 7.87 13.33 9.64 9.21 8.32 6.96 5.87 13.99 1.62 7.40 7.35 47
2007 7.94 13.96 9.65 9.12 8.42 7.35 6.57 12.87 1.61 7.65 7.62 48
2008 7.79 13.99 9.63 8.43 8.26 7.64 7.44 12.90 1.41 7.97 7.90 51
2009 7.65 13.98 9.62 8.37 8.15 7.51 7.23 13.08 1.28 7.86 7.79 50
2010 7.51 14.00 9.61 8.36 8.02 7.40 7.57 14.86 1.27 7.98 7.86 52
2011 7.22 14.02 9.69 8.33 7.78 6.82 7.89 14.51 1.46 7.55 7.36 49
2012 6.92 14.11 9.68 8.34 7.54 6.67 7.59 13.02 1.38 7.26 7.09 47
2013 6.76 14.64 9.68 8.34 7.43 6.18 6.55 12.78 1.31 6.78 6.61 44
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TABLE 2 Prevalence of OST by country and year (continued )
Year
CPRD coverage by country (%) Prevalence by countrya UK adjusted
England Wales Scotland Northern Ireland UK England Wales Scotland Northern Ireland UK Prevalencea nb
2014 5.93 14.37 9.74 8.34 6.72 5.16 5.05 12.31 1.05 5.87 5.64 38
Trendc 1.023 1.050 0.989 1.009 1.022 1.020 1.026
SE (trend)c 1.18 4.12 2.20 12.32 1.01 0.26 0.26
p-value < 0.0001 < 0.0001 < 0.0001 0.4786 < 0.0001 < 0.0001 < 0.0001
Deviation < 0.0001 < 0.0001 < 0.0001 0.9747 < 0.0001 < 0.0001 < 0.0001
SE, standard error.
a Prevalence rate (per 10,000 patients).
b In thousands.
c Trend is multiplicative.
Notes
Approximate SEs are reported multiplied by a factor of 1000.
Prevalence estimates were calculated as the observed number of OST patients divided by the number of CPRD patients. For the UK, an adjusted prevalence rate estimate was calculated
from the expected OST patients for each country within the UK (using the CPRD coverage) and the number of UK-registered patients (see Appendix 4).
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Trends in patient characteristics
The average age of OST patients increased by 10 years during the study (Table 3). About half of this
increase was attributable to an ageing sample of patients receiving prolonged OST over many episodes.
There was little evidence that the gender ratio varied during the study period. However, this concealed a
declining trend in the ratio for the under-30-year-olds, with men representing 70% of this group in 1998
compared with 60% in 2014 (p < 0.0001).
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FIGURE 3 Prevalence of OST by country and year. All countries except Northern Ireland showed non-linear trends
in the prevalence of OST by year. The non-linearity reflected an increasing trend in the earlier years followed by a
decline in the prevalence. The timing of the decline varied by country and may have started earliest in Scotland,
followed by England, with Wales showing the latest downturn. Northern Ireland showed a constant prevalence of
OST for each year studied.
TABLE 3 Patient characteristics by year
Year
OST
patients
Age
(years)
Gender
(% male)
Medications (% of patients)
M B D BD ZD PG
1998 1160 32.78 68.10 86.03 8.45 15.00 42.07 10.78 0.60
1999 1707 32.43 67.72 85.82 7.79 15.35 37.26 12.71 0.64
2000 1948 33.04 68.84 83.21 10.22 17.30 37.47 13.86 0.87
2001 2357 33.43 68.22 77.94 18.24 17.95 35.51 12.13 0.93
2002 2805 33.90 67.45 73.16 23.78 16.51 36.72 13.58 1.21
2003 3274 34.16 67.78 71.90 27.09 12.98 34.18 12.16 1.56
2004 3574 34.57 67.04 69.56 30.64 11.58 32.18 11.39 2.52
2005 3783 35.26 66.93 68.89 32.30 11.10 32.88 12.00 2.88
2006 3978 36.25 68.00 69.43 31.57 10.41 33.43 13.70 3.14
2007 4118 37.21 67.53 69.31 30.67 10.13 32.25 12.94 4.15
2008 4276 37.95 67.45 71.02 29.09 9.10 32.16 12.04 4.07
continued
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During the study, the use of methadone, dihydrocodeine and benzodiazepines was decreasing while
the use of buprenorphine and gabapentinoids was increasing (Figure 4). Deviations from linearity for
methadone and buprenorphine suggested that the major changes occurred up to 2006, with less evidence
of any changes after that date. Although there was evidence of a declining prevalence for the prescription
of z-drugs, the effect size was small, reflecting a prevalence among OST patients of ≈12. Considering
the prevalence of any of these three medications, the prevalence was declining up to 2002 but with no
strong evidence of any change after that year. Overall, 78.6% [95% confidence interval (CI) 77.9%
to 79.3%], 36.0% (95% CI 35.2% to 36.9%), 15.4% (95% CI 14.7% to 16.0%), 47.4% (95% CI
46.6% to 48.3%), 25.4% (95% CI 24.6% to 28.1%) and 9.2% (95% CI 6.7% to 9.7%) of patients
were prescribed methadone, buprenorphine, dihydrocodeine, benzodiazepines, z-drugs or
gabapentinoids, respectively.
Trends in episode characteristics
Overall, average dose increased during the study, although there was evidence that this trend may have
changed after 2008 (Table 4). Linear trends after this date showed a decreasing effect, with –1.057
(95% CI –1.123 to –0.966) and –0.151 (95% CI –0.177 to –0.126) for methadone and buprenorphine,
respectively. Both medications showed an increasing adherence to guidelines with optimal dose across the
whole study. However, the deviation statistics suggested a more complex pattern. After 2008, methadone
episodes showed a declining adherence, multiplicative trend (0.96, 95% CI 0.94 to 0.99), whereas
buprenorphine showed no trend (1.02, 95% CI 0.99 to 1.06).
TABLE 3 Patient characteristics by year (continued )
Year
OST
patients
Age
(years)
Gender
(% male)
Medications (% of patients)
M B D BD ZD PG
2009 4188 38.60 66.52 72.11 27.72 8.55 31.45 12.30 4.75
2010 4129 39.42 67.35 73.12 26.64 8.09 30.35 12.62 6.32
2011 3919 40.16 67.44 73.03 25.85 7.76 30.62 12.78 7.76
2012 3681 40.82 67.24 70.99 27.68 7.25 30.05 12.66 9.07
2013 3413 41.47 67.07 69.32 29.62 7.47 28.66 11.10 11.08
2014 2670 42.55 67.45 67.57 30.82 7.68 26.89 10.90 12.70
Overall 12,780 36.04 66.63 78.62 36.03 15.37 47.44 25.37 9.20
Trenda 0.681 0.997 0.971 1.036 0.930 0.971 0.995 1.213
SE (trend) 0.0099 0.0021 0.0023 0.0025 0.0032 0.0021 0.0030 0.0058
p-value < 0.0001 0.2119 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.1149 < 0.0001
Deviation < 0.0001 0.9956 < 0.0001 < 0.0001 < 0.0001 0.0790 0.0070 0.3984
B, buprenorphine; BD, benzodiazepines; D, dihydrocodeine; M, methadone; PG, pregabalin/gabapentin; SE, standard error;
ZD, z-drugs.
a Trend is additive for age and multiplicative for all other outcomes.
Note
The totals of the percentages exceed 100% as a result of some patients being prescribed multiple medications within any
given year.
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The predicted median durations by year are shown in Table 4. The mean durations are not reported
because of the skewed nature of the distribution. On-treatment duration reached a maximum in 2010 for
methadone (Figure 5). By contrast, duration for buprenorphine was still increasing by the end of the study.
Off-treatment durations were generally increasing throughout the study but there were periods when
duration appeared to be constant. For methadone, there was no evidence of any increase before 2009
(HR 1.01, 95% CI 1.00 to 1.02; p = 0.180). Similarly, for buprenorphine, during the period 2002–8,
off-treatment duration remained constant (HR 1.01, 95% CI 0.99 to 1.03; p = 0.306).
The associations of gender, age, comorbidity and region with on- and off-durations are reported in Table 5.
Age and gender were associated with on-treatment duration for buprenorphine only, with older women
tending to have longer durations (lower HR). Those with comorbid chronic illnesses tended to have longer
durations for both medications. For off-treatment duration, gender had no association with either medication
and comorbidity had no association with buprenorphine. Older patients tended to have longer intervals
between treatments. Adjusting for these variables did not markedly change the duration results (Table 6).
In a sensitivity analysis, we also analysed duration using the start year of on or off treatment rather than
each year associated with an episode. This had two consequences: (1) episodes with on/off treatment
starting before the study start date were excluded and (2) an episode contributed to only 1 year however
long the period on/off treatment. As a result, it was appropriate to consider each episode as only a single
record. Despite these changes to the data, the median durations were very similar (Table 7).
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FIGURE 4 Opiate substitution treatment medications, benzodiazepines, z-drugs and gabapentinoids prescribed
to OST patients by year. Overall, during the study, prescriptions of methadone declined, whereas those for
buprenorphine increased. There may be some evidence to suggest that, after 2007, the percentage of OST patients
prescribed these medications remained constant. Benzodiazepines and z-drugs were prescribed to a declining
proportion of OST patients as time progressed. Gabapentinoids were increasingly prescribed, from < 1% in 1998 to
> 10% in 2014.
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TABLE 4 Episode characteristics by methadone or buprenorphine episodes and by year
Year
Number of episodes Mean dose (mg) Optimal dose (%) On-treatment duration (days) Off-treatment duration (days)
M B Other M B M B M B All M B All
1998 1062 97 425 41.95 2.30 25.08 16.67 76 57 82 182 89 163
1999 1366 166 619 40.86 2.47 26.79 8.96 66 36 69 206 74 172
2000 1526 199 842 39.11 2.80 21.45 7.62 58 29 62 177 101 166
2001 1698 351 1146 40.99 3.04 27.39 14.80 77 41 75 179 125 173
2002 1885 579 1323 43.67 4.28 34.72 18.92 80 45 80 182 144 179
2003 2109 776 1406 46.21 5.13 41.59 23.93 100 46 91 172 146 168
2004 2180 885 1506 48.05 5.47 45.36 28.35 98 47 93 196 148 176
2005 2077 998 1609 51.28 6.21 51.01 30.15 122 48 103 204 142 175
2006 2232 1025 1682 53.66 6.46 56.17 25.80 134 48 108 195 142 175
2007 2366 1017 1686 55.71 7.30 60.48 31.40 141 42 102 199 165 181
2008 2560 996 1601 57.00 7.32 63.97 33.89 151 48 110 186 149 169
2009 2507 999 1559 56.30 7.27 62.69 27.91 144 46 102 220 137 179
2010 2497 931 1441 56.83 7.27 61.98 31.19 178 53 122 209 152 181
2011 2376 868 1288 54.82 6.70 63.65 29.57 140 52 107 259 150 197
2012 2145 911 1158 52.50 6.62 62.87 33.45 121 61 99 254 151 197
2013 1928 851 1016 52.20 6.94 59.38 32.67 94 58 82 219 161 185
2014 1405 626 716 52.64 7.17 55.76 36.36 68 62 64 293 198 248
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Year
Number of episodes Mean dose (mg) Optimal dose (%) On-treatment duration (days) Off-treatment duration (days)
M B Other M B M B M B All M B All
Overall 17,787 8497 8143 51.66 6.54 48.58 28.49 106 48 93 202 146 179
Trenda 0.959 0.198 1.131 1.061 1.048 1.028 1.020 1.023 1.024 1.013
SE (trend) 0.0030 0.0013 0.0036 0.0065 0.0033 0.0047 0.0025 0.0026 0.0039 0.0020
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Deviation < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 0.0952 < 0.0001 < 0.0001 < 0.0001 0.0002
B, buprenorphine only; M, methadone only; SE, standard error.
a Trend is additive for mean dose and multiplicative for all other outcomes.
Notes
‘Other’ medication regimes included dihydrocodeine and multiple medications.
Optimal doses are reported as percentage of episodes with ≥ 60mg methadone or ≥ 12mg buprenorphine.
Median durations were estimated by parametric survival analysis using a log-normal distribution.
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Summary
Our data suggest that the prevalence of OST has been declining since 2010. Extrapolation to the whole UK
suggests that < 50,000 patients are currently being treated in primary care. This number is lower than
other estimates9,11 and may reflect either other patients being treated by alternative services such as
community drug agencies or that CPRD practices were not representative of all UK general practices.
Trends in medications suggest that prescribing buprenorphine has become more prevalent, with about
30% of patients in 2014 prescribed this medication. Co-prescription of gabapentinoids was rare at the
start of this study but by the end it was prescribed to about 13% of patients. Benzodiazepines were more
commonly co-prescribed but the prevalence of this medication among OST patients per year declined,
although they were still prescribed to about 26% of patients by the end of the study. The prevalence of
co-prescription of z-drugs changed very little during the study.
The mean doses and the proportion of treatment episodes reaching an optimal dose increased up to
about 2008, with evidence of declining trends after this date for most outcomes. The exception was
optimal dose for buprenorphine for which the evidence suggested a stable proportion post 2008. Shorter
treatment duration for buprenorphine than for methadone treatment has also been reported in other
studies.16,21–23,63 Off-treatment durations increased for both methadone and buprenorphine after 2008.
It is interesting to note that the shorter on-treatment duration for buprenorphine was associated with a
shorter off-treatment duration.
Year
1998 2000 2005 2010 2014
M
ed
ia
n
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ti
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d
ay
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200
150
100
50
0
Methadone
Buprenorphine
All episodes
Medication
FIGURE 5 Duration of OST by type and year. The median duration of buprenorphine treatment increased overall
during the study, although there was some variability in the early years owing to the small number of episodes.
Methadone episodes showed an increasing duration up to 2010 but then decreased such that in 2014 their
durations were similar to those of buprenorphine.
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TABLE 5 Effect of confounders for on- and off-treatment duration by OST type
Confounder Category
On treatment Off treatment
Methadone Buprenorphine Methadone Buprenorphine
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Gender Male 0.99 (0.94 to 1.06) 0.8483 1.25 (1.16 to 1.35) < 0.0001 0.97 (0.93 to 1.02) 0.2704 1.01 (0.96 to 1.08) 0.6385
Female 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Age (years) < 30 1 (reference) 0.2908 1 (reference) < 0.0001 1 (reference) < 0.0001 1 (reference) < 0.0001
30–39 1.06 (0.99 to 1.14) 1.14 (1.02 to 1.27) 0.82 (0.77 to 0.86) 0.93 (0.85 to 1.02)
40–49 1.05 (0.97 to 1.15) 0.91 (0.81 to 1.02) 0.62 (0.57 to 0.66) 0.61 (0.55 to 0.66)
≥ 50 1.10 (0.97 to 1.24) 0.72 (0.65 to 0.81) 0.54 (0.49 to 0.60) 0.42 (0.38 to 0.46)
Comorbidity score 0 1 (reference) < 0.0001 1 (reference) 0.0251 1 (reference) < 0.0001 1 (reference) 0.2837
1 1.01 (0.94 to 1.08) 0.98 (0.90 to 1.06) 0.91 (0.86 to 0.96) 0.98 (0.92 to 1.05)
≥ 2 0.64 (0.57 to 0.73) 0.84 (0.74 to 0.95) 0.76 (0.69 to 0.85) 1.07 (0.97 to 1.18)
Region North East 1.29 (1.00 to 1.66) < 0.0001 1.38 (1.11 to 1.70) < 0.0001 1.21 (0.98 to 1.48) < 0.0001 0.79 (0.67 to 0.92) < 0.0001
North West 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Yorkshire and the Humber 1.85 (1.61 to 2.14) 1.89 (1.53 to 2.35) 1.52 (1.34 to 1.71) 1.08 (0.91 to 1.29)
East Midlands 1.32 (1.13 to 1.53) 1.33 (1.12 to 1.58) 1.40 (1.24 to 1.59) 0.95 (0.83 to 1.09)
West Midlands 1.80 (1.62 to 2.01) 1.12 (0.98 to 1.28) 1.72 (1.57 to 1.88) 1.13 (1.02 to 1.26)
East 1.45 (1.29 to 1.62) 1.27 (1.09 to 1.48) 1.49 (1.36 to 1.63) 1.17 (1.04 to 1.32)
continued
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TABLE 5 Effect of confounders for on- and off-treatment duration by OST type (continued )
Confounder Category
On treatment Off treatment
Methadone Buprenorphine Methadone Buprenorphine
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
South West 1.88 (1.68 to 2.10) 1.22 (1.06 to 1.41) 1.72 (1.56 to 1.89) 1.06 (0.95 to 1.18)
South Central 2.31 (2.05 to 2.61) 1.16 (1.01 to 1.32) 1.63 (1.48 to 1.80) 1.08 (0.97 to 1.20)
London 2.30 (2.03 to 2.62) 1.19 (1.03 to 1.39) 1.46 (1.32 to 1.62) 0.89 (0.80 to 1.00)
South East 1.12 (0.95 to 1.33) 1.03 (0.86 to 1.22) 1.90 (1.66 to 2.18) 1.11 (0.97 to 1.27)
Northern Ireland 1.62 (0.83 to 3.16) 1.38 (0.99 to 1.90) 2.13 (1.20 to 3.79) 0.61 (0.48 to 0.78)
Scotland 3.37 (3.10 to 3.66) 1.12 (0.92 to 1.37) 1.45 (1.35 to 1.55) 1.24 (1.05 to 1.46)
Wales 1.98 (1.71 to 2.29) 1.79 (1.52 to 2.09) 2.27 (2.01 to 2.57) 1.28 (1.12 to 1.45)
All effects are mutually adjusted and adjusted for year.
On treatment: interactions with OST type: p< 0.0001 (gender), p < 0.0001 (age), p= 0.0107 (comorbidity) and p< 0.0001 (region).
Off treatment: interactions with OST type: p= 0.3127 (gender), p < 0.0001 (age), p< 0.0001 (comorbidity) and p< 0.0001 (region).
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TABLE 6 Median episode duration by year and type of medication adjusted for four confounders
Year
On-treatment duration (days) Off-treatment duration (days)
Methadone
(only)
Buprenorphine
(only) Alla
Methadone
(only)
Buprenorphine
(only) Alla
1998 93 73 87 170 126 150
1999 81 43 75 194 98 160
2000 71 33 68 175 126 158
2001 87 43 79 175 132 163
2002 87 46 81 178 140 168
2003 104 46 91 169 135 158
2004 106 48 95 193 139 167
2005 137 49 110 204 137 171
2006 158 49 120 201 139 177
2007 162 43 113 211 164 189
2008 171 51 122 197 155 180
2009 158 51 115 232 148 194
2010 189 59 136 218 165 200
2011 153 59 124 284 171 228
2012 137 67 114 279 164 224
2013 102 64 93 250 176 217
2014 67 70 70 327 216 288
Overall 120 51 101 206 151 184
Trendb 1.041 1.034 1.028 1.034 1.030 1.031
SE (trend) 0.0034 0.0049 0.0026 0.0027 0.0038 0.0020
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Deviation < 0.0001 0.0355 < 0.0001 < 0.0001 0.2703 < 0.0001
SE, standard error.
b Trend is multiplicative for all other outcomes.
a All types and combinations of medications.
Notes
Median durations were estimated by parametric survival analysis using a log-normal distribution. Adjusted for patient age,
gender and comorbidity and UK region. Interaction of year with type: p< 0.0001 (on treatment), p = 0.0178 (off treatment).
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TABLE 7 Median episode duration by start year and type of medication
Year
On-treatment duration (days) Off-treatment duration (days)
Methadone
(only)
Buprenorphine
(only) Alla
Methadone
(only)
Buprenorphine
(only) Alla
1998 72 65 78 208 81 180
1999 63 36 67 193 83 169
2000 63 28 67 174 97 164
2001 75 41 73 175 142 174
2002 85 47 85 186 152 182
2003 105 46 96 178 140 169
2004 100 48 94 206 150 180
2005 132 47 108 190 145 171
2006 143 50 110 192 138 169
2007 142 44 104 200 164 180
2008 149 49 110 185 145 166
2009 139 47 99 217 134 177
2010 168 51 115 221 159 187
2011 130 52 102 264 147 198
2012 121 61 97 257 159 203
2013 85 57 77 226 163 192
2014 73 58 69 362 199 279
Overall 106 48 93 203 146 180
Trendb 1.0470 1.0240 1.0186 1.0240 1.0225 1.0129
SE (trend) 0.0033 0.0048 0.0026 0.0027 0.0039 0.0020
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Deviation < 0.0001 0.0480 < 0.0001 < 0.0001 < 0.0001 < 0.0001
SE, standard error.
b Trend is multiplicative for all other outcomes.
a All types and combinations of medications.
Note
Interaction of year with type: p < 0.0001 (on and off treatment).
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Chapter 5 Comparison of methadone and
buprenorphine use in opiate substitution treatment
As seen in the previous chapter, there has been an increase in the use of buprenorphine as part of OST.This chapter, on WP 2, presents the results comparing buprenorphine and methadone on mortality.
The main report is published in Hickman et al.61 Reproduced from Hickman et al.61 This is an Open Access
article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below
includes minor additions and formatting changes to the original text.
Aims and objectives
Our main aim was to explore the differences in mortality risk between methadone and buprenorphine and
whether or not any effects were modified by treatment period. Our secondary aim was to explore other
interactions that may influence the risk of mortality.
Data set for main analyses
There were 26,546 OST episodes involving solely methadone or buprenorphine relating to 11,033 patients. For
simplicity in comparing these medications, treatment episodes involving both medications or dihydrocodeine
were excluded. In 30,410 person-years of follow-up there were 587 ACM deaths.
Statistical methods
Poisson regression was the main analytic method. In addition to standard adjusted analyses, three methods,
more robust to residual confounding were described in the paper: IPW, IV and PSM. Further details are
provided below on the IV and PSM analyses.
Sensitivity analyses were performed:
1. Restricting to patients without any evidence of comorbid illnesses. This was to explore whether or not
chronic illnesses may have introduced residual confounding, perhaps via palliative care.
2. Including partial episodes involving methadone or buprenorphine. Main analyses involved only episodes
involving a single medication to avoid any possible combined effect of multiple medications during an
episode. Including episodes with multiple medications allowed a more continuous follow-up of patients,
increasing person-years by 19% and the number of deaths by 12%.
3. Additionally adjusting for the tapering of dose during the last 28 days of treatment. Tapering may
indicate a planned discharge from treatment rather than poor treatment retention.
4. Using negative binomial regression to take account of possible overdispersion in Poisson regression.
5. Using linear regression and survival analysis to compare the results for risk differences and HRs with IRRs.
6. Using multilevel models to explore whether other sources of variability, in particular between patients,
modify the interpretation of results.
7. Analysing only the first or last episode for each patient to investigate whether there was a cumulative
effect of multiple episodes.
8. Redefining OST episodes based on a 7-day or 56-day gap instead of the 28-day gap used in main analyses.
Items 1–4 were included in the published paper, although additional background results are included in
Tables 8–11. Items 5–8 were not included in the published paper but are included now for completeness.
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Propensity score matching
As well as IPW, propensity scores were also used to match buprenorphine episodes to methadone
episodes using the nearest neighbour procedure. Matching was successful if the difference in logit
(propensity score) was ≤ 0.25 SD.46 For our data, the SD of the logit was 1.28, suggesting a criterion of
0.32. Owing to the limited pool of methadone episodes, it was not always possible to match every
buprenorphine episode to a methadone episode using this criterion.
Matching reduced the data to 13,940 (53% of total) and 8938 (57%) episodes for ACM and DRP, respectively.
The results from Poisson regressions are shown in Table 8. Adjusted results are similar to unadjusted results,
suggesting that matching had reduced observed confounding below any level of practical significance.
TABLE 8 Poisson analyses of OST type and period on mortality using matched episodes
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
All-cause mortality
On 1–4 weeks 3.02 (2.06 to 4.44) < 0.0001 2.77 (1.88 to 4.09) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 10.22 (7.95 to 13.13) 10.09 (7.80 to 13.06)
Off rest 2.03 (1.59 to 2.60) 2.60 (2.02 to 3.35)
On 1–4 weeks Methadone 1 (reference) 0.0003 1 (reference) 0.0031
Buprenorphine 0.07 (0.02 to 0.29) 0.0003 0.07 (0.02 to 0.29) 0.0002
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.36 (0.22 to 0.59) < 0.0001 0.28 (0.17 to 0.46) < 0.0001
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.10 (0.06 to 0.19) < 0.0001 0.09 (0.05 to 0.16) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.39 (0.26 to 0.56) < 0.0001 0.27 (0.18 to 0.39) < 0.0001
Drug-related mortality
On 1–4 weeks 1.28 (0.30 to 5.53) < 0.0001 1.30 (0.30 to 5.68) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 7.36 (3.58 to 15.16) 7.62 (3.63 to 16.01)
Off rest 2.52 (1.35 to 4.69) 2.61 (1.38 to 4.96)
On 1–4 weeks Methadone 1 (reference) 0.1391 1 (reference) 0.1186
Buprenorphine n/e n/e
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.61 (0.20 to 1.87) 0.3893 0.54 (0.17 to 1.65) 0.2781
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 1.46 (0.48 to 4.46) 0.5078 1.42 (0.46 to 4.35) 0.5382
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.34 (0.13 to 0.85) 0.0206 0.31 (0.12 to 0.78) 0.0130
n/e, not estimated because there were zero deaths.
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Notes
Based on 13,940 or 8938 matched episodes (410 all-cause or 56 drug-related deaths).
Main effect and interaction p-values (2 or 3 df) are shown in bold.
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A comparison of PSM results with confounder and IPW adjusted results in the main paper61 showed similar
effects in terms of the point estimates. However, the CIs for PSM results were wider.
Owing to the reduced number of data for these analyses, for DRP, the full interaction between period and
type could not be estimated because there were zero deaths observed for buprenorphine treatment in the
first 4 weeks. Estimates of the partial interaction (with 2 df instead of 3 df) were obtained by excluding all
data for buprenorphine in the first 4 weeks of treatment.
Instrumental variable analysis
We explored the usefulness of a GP’s previous prescription as an IV.58,59 Because a treatment episode typically
involved many prescriptions, we concentrated on the initiation of treatment as the critical time when the choice
of medication was made. There were 3409 GPs associated with prescribing methadone or buprenorphine at
this time. Their histories of treatment initiation covered 26,546 episodes, with an additional 728 episodes
predating the study period (Figure 6). Because the time of day was unavailable for prescriptions within CPRD,
4560 episodes (13%) initiated on the same day by the same GP were assigned a random generation sequence.
There were sufficient histories to provide information on the previous prescription for 2213 GPs (65%).
The majority of GPs tended to have a history of prescribing only one type of medication at the initiation of
treatment, with 1269 (37%) prescribing methadone and 959 (28%) prescribing buprenorphine. However,
these GPs were generally associated with shorter histories such that these 65% of GPs accounted for only
8606 (25%) episodes. These GPs were excluded from the IV analyses.
Analysis of OST type
(Data set: GPs; episodes; patients; deaths)
• All cause: n = 3409, n = 26,546, n = 11,033, n = 587
• Drug related: n = 1958, n = 15,600, n = 5935, n = 87
• All cause: n = 2213, n = 25,350, n = 10,513, n = 520
• Drug related: n = 1266, n = 14,908, n = 5646, n = 80
• All cause: n = 2213, n = 23,865, n = 10,057, n = 472
• Drug related: n = 1266, n = 14,152, n = 5445, n = 76
• All cause: n = 1160, n = 19,021, n = 8419, n = 357
• Drug related: n = 729, n = 12,046, n = 4852, n = 67
Insufficient GP history
When the GP has prescribed methadone
or buprenorphine for only one episode
• All cause: n = 1196, n = 1196, n = 520, n = 67
• Drug related: n = 692, n = 692, n = 289, n = 7
Missing data for first GP episode
The previous prescription is missing for
the first GP episode but for 728 all-cause
(510 drug-related) episodes this occured
before the study start date
• All cause: n = 0, n = 1485, n = 456, n = 48
• Drug related: n = 0, n = 756, n = 201, n = 4
• All cause: n = 1053, n = 4844, n = 1638, n = 115
• Drug related: n = 537, n = 2106, n = 593, n = 9
GP prescribed only one medication
FIGURE 6 Flow chart of data available for IV analyses. The previous GP prescription was used as an IV. About 35%
of GPs had initiated an OST episode on only one occasion and so were excluded from the analyses. For 33–40% of
GPs, data were available before the study start date. Hence, the number of available episodes did not reduce by
the number of GPs. GPs who prescribed only one medication, either methadone or buprenorphine, were also
excluded as the IV would be equivalent to the prescribed medication and its associated confounding.
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Using the previous prescription as an IV reduced the sample to 8419 patients, 19,021 episodes and
357 deaths in ACM analyses, and 4852 patients, 12,046 episodes and 67 deaths in DRP analyses.
The proportions of buprenorphine episodes, 34%, remained similar to the 35% for current prescriptions.
By contrast, the proportion of those episodes associated with deaths, 31%, doubled from the 14% with
current prescriptions.
An investigation of the criteria for a valid IV showed strong associations between the choice of prescribed
medication and IVs. Agreement occurred in 71% of episodes for ACM and in 70% of episodes for DRP.
However, the IV remained associated with confounders with an R2 of 10.5% and 6.1% for ACM and DRP,
respectively. These associations were similar to those observed between OST type and confounders
(Table 9a). These results suggested that previous prescription would act as a poor IV. Similar conclusions
were reached when regression coefficients were compared (Table 9b).
Confounding
In the main report, confounding was assessed using unadjusted associations of predictors (in the propensity
score model) with OST type. Comparing the predicted probabilities of being prescribed buprenorphine,
the differences between categories for each predictor were reduced in IPW and PSM models compared
with an unadjusted model (see table S2 in Hickman et al.61). For instance, the differences between men
and women in being prescribed buprenorphine reduced from 7% in an unadjusted model to 0.5% in the
IPW model. In Table 9, we extend these analyses to report the multivariable associations between OST type
and all confounders. These analyses were based on linear regressions between OST type (or the IV acting
as a proxy for OST type) and confounders using the weights implicit in the Poisson regressions on mortality.
Comparisons were made with the standard covariate adjusted model. In part (a), R2 statistics are reported
for individual confounders and overall. In part (b), the regression coefficients for the multivariable models
TABLE 9a Degree of confounding and matching for OST type by analysis type: summary of associations
Confoundinga
Type of analysis
Adjusted IPW PSM IV
Gender 0.33 0.01 0.05 0.19
Age 5.64 0.04 0.17 4.45
Year 0.01 0.69 1.21 0.63
Comorbidity score 2.90 0.52 0.79 2.27
Region 5.75 1.72 1.53 6.47
All 11.38 3.16 3.60 10.52
Matchingb 1.27 0.17 0.01 1.22
n (episodes) 26,546 26,546 13,940 19,021
n (patients) 11,033 11,033 5921 7582
n (deaths) 587 587 410 357
a Degree of confounder was assessed by R2 (%) from linear regressions of OST type on all five confounders. Independent
contributions of each confounder are also reported.
b Matching was assessed by linear regressions of OST type on logit(propensity score). When the IV (previous prescription
by the GP) was for a different medication from the current prescription, the logit was negated. The results reflect the
estimated effect of difference between OST types (buprenorphine minus methadone).
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are reported. Both PSM and IPW reduced the associations with observed confounders, although the
association with calendar year increased.
A comparison of confounder associations with mortality showed that all variables were associated with
either ACM or DRP. Gender had a stronger association with DRP, whereas age and region had a stronger
association with ACM (Table 10).
TABLE 9b Degree of confounding and matching for OST type by analysis type: effect sizes from multiple linear
regressions of OST type on confounders
Variable Category
Type of analysis
Adjusted IPW PSM IV
Gender Male –0.017 0.008 0.005 –0.016
Female 0 (reference)
Age (years) < 30 0 (reference)
30–39 0.018 0.023 0.014 –0.010
40–49 0.059 0.042 0.054 0.011
≥ 50 0.162 0.001 0.014 0.145
Year 1998–9 0 (reference)
2000–4 0.002 –0.103 –0.149 0.018
2005–9 –0.015 –0.133 –0.183 0.093
2010–14 –0.029 –0.140 –0.190 0.062
Comorbidity score 0 0 (reference)
1 –0.004 –0.010 0.001 0.001
≥ 2 0.057 0.068 0.080 0.066
Region North East 0.362 0.159 0.160 0.336
North West 0 (reference)
Yorkshire and the Humber 0.110 0.029 0.035 0.064
East Midlands 0.146 0.066 0.086 0.181
West Midlands 0.089 –0.005 –0.006 0.063
East 0.052 0.009 0.017 0.050
South West 0.006 –0.045 –0.044 0.079
South Central 0.130 0.026 0.029 0.127
London –0.028 –0.052 –0.064 –0.043
South East 0.096 –0.001 0.074 0.093
Northern Ireland 0.045 –0.140 –0.167 0.097
Scotland –0.053 –0.041 0.011 –0.180
Wales 0.081 –0.039 –0.005 0.146
R2 (%) 11.38 3.16 3.60 10.52
Note
Effect sizes reflect differences in the propensity to receive buprenorphine.
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Key findings from the published paper
The overall mortality rates for ACM and DRP were 1.93 and 0.53 per 100 person-years, respectively.
DRP was elevated in the first 4 weeks of treatment (IRR 1.93, 95% CI 0.97 to 3.82), the first 4 weeks after
treatment ceased (IRR 8.15, 95% CI 5.45 to 12.19) and the remainder of time out of treatment (IRR 2.13,
95% CI 1.47 to 3.09), compared with mortality risk from 4 weeks to the end of treatment. Similar patterns
of elevated risks by period were also observed for ACM, although the tendency was for higher IRRs than
for DRP (first 4 weeks of treatment, IRR 2.98, 95% CI 2.44 to 3.64; first 4 weeks after treatment ceased,
IRR 10.40, 95% CI 9.07 to 11.92; and the remainder of time out of treatment, IRR 2.77, 95% CI 2.42
to 3.17).
TABLE 10 Mutually adjusted associations of confounders with mortality
Confounder Category
All-cause mortality Drug-related mortality
IRR (95% CI) p-value IRR (95% CI) p-value
Gender Male 1.13 (0.95 to 1.34) 0.1769 4.08 (2.04 to 8.15) 0.0001
Female 1 (reference) 1 (reference)
Age (years) < 30 1 (reference) < 0.0001 1 (reference) 0.5135
30–39 1.20 (0.85 to 1.71) 1.12 (0.62 to 2.02)
40–49 2.06 (1.45 to 2.92) 0.89 (0.44 to 1.79)
≥ 50 3.27 (2.31 to 4.65) 0.65 (0.28 to 1.54)
Year 1998–9 1 (reference) 0.0028 1 (reference) 0.0210
2000–4 0.72 (0.50 to 1.03) 0.40 (0.20 to 0.82)
2005–9 0.65 (0.46 to 0.93) 0.33 (0.16 to 0.68)
2010–14 0.54 (0.37 to 0.77) 0.37 (0.18 to 0.79)
Comorbidity score 0 1 (reference) < 0.0001 1 (reference) 0.0007
1 1.39 (1.08 to 1.79) 1.50 (0.92 to 2.46)
≥ 2 11.68 (9.48 to 14.40) 3.85 (1.90 to 7.81)
Region North East 1.03 (0.53 to 2.01) 0.0003 n/e 0.2529
North West 1 (reference) 1 (reference)
Yorkshire and the Humber 1.64 (1.07 to 2.53) 0.25 (0.03 to 1.81)
East Midlands 1.69 (1.10 to 2.61) 0.87 (0.26 to 2.90)
West Midlands 0.92 (0.62 to 1.35) 0.60 (0.28 to 1.25)
East 1.88 (1.36 to 2.61) 1.46 (0.75 to 2.84)
South West 1.08 (0.74 to 1.59) 0.91 (0.46 to 1.77)
South Central 0.93 (0.63 to 1.38) 0.44 (0.17 to 1.15)
London 1.31 (0.92 to 1.87) 0.93 (0.43 to 2.00)
South East 1.50 (0.95 to 2.38) 1.43 (0.59 to 3.49)
Northern Ireland 0.53 (0.13 to 2.17) n/a
Scotland 1.39 (1.03 to 1.87) n/a
Wales 0.95 (0.63 to 1.43) n/a
n/a, data not available; n/e, not estimated as effect assumed to be same as for North West.
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Patients on buprenorphine had lower ACM rates in each treatment period than those on methadone, with
the strongest beneficial effect being associated with the first 4 weeks of treatment (IRR 0.04, 95% CI 0.01
to 0.15). After IPW adjustment, there was evidence of a lower DRP risk for patients on buprenorphine than
for those on methadone at treatment initiation (IRR 0.08, 95% CI 0.01 to 0.48) and for the rest of time on
treatment (IRR 0.37, 95% CI 0.17 to 0.79). Model estimates suggested that there was a low probability
that methadone or buprenorphine reduced the number of DRPs in the population: 28% and 21%,
respectively.
There was evidence that age and comorbidity interacted with OST type (p < 0.0024) such that buprenorphine
may have lower ACM and DRP risks in older and more comorbid patients.
Sensitivity analyses did not change the conclusions (see table S4 in Hickman et al.61).
Other sensitivity analyses not reported in published paper
An analysis of risk differences involved linear regression on the mortality rate associated with each record
in the data file. The length of time associated with each record was used as a weight in the analysis. These
analyses might provide an alternative description of risks to IRRs. Although the ordinal properties of these
results matched those from Poisson regression (e.g. the treatment period with the lowest risk was on
treatment after the first 4 weeks, and the highest was off treatment in the first 4 weeks), there were
power issues for the treatment period effect for DRP (Table 11). This possibly reflected the low mortality
rate for the reference period in DRP, producing a smaller range of differences in the linear regressions but
a larger range in the ratios for the Poisson regressions.
TABLE 11 Linear regression analyses of OST type and period on mortality
Period OST type
Unadjusted Adjusteda
RD (95% CI) p-value RD (95% CI) p-value
All-cause mortality
On 1–4 weeks 2.13 (–0.03 to 4.30) < 0.0001 2.31 (0.13 to 4.50) < 0.0001
On rest 0 (reference) 0 (reference)
Off 1–4 weeks 8.56 (6.50 to 10.61) 8.70 (6.62 to 10.78)
Off rest 1.21 (0.15 to 2.26) 1.67 (0.58 to 2.76)
On 1–4 weeks Methadone 0 (reference) < 0.0001 0 (reference) < 0.0001
Buprenorphine –4.05 (–8.47 to 0.38) 0.0734 –5.95 (–10.41 to –1.50) 0.0088
On rest (reference) Methadone 0 (reference) 0 (reference)
Buprenorphine –0.46 (–1.98 to 1.06) 0.5513 –2.11 (–3.70 to –0.52) 0.0093
Off 1–4 weeks Methadone 0 (reference) 0 (reference)
Buprenorphine –11.40 (–15.47 to –7.34) < 0.0001 –13.63 (–17.73 to –9.53) < 0.0001
Off rest Methadone 0 (reference) 0 (reference)
Buprenorphine –1.05 (–2.91 to 0.80) 0.2667 –2.95 (–4.86 to –1.05) 0.0024
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We also more formally took account of the effect of the censoring of follow-up by performing survival
analysis instead of Poisson regression (Table 12). Right-censoring occurred when patients left a CPRD
primary care practice, or if treatment episodes extended beyond the study end or CPRD’s last data
collection dates. The results of this analysis were very similar to the adjusted Poisson results.
TABLE 11 Linear regression analyses of OST type and period on mortality (continued )
Period OST type
Unadjusted Adjusteda
RD (95% CI) p-value RD (95% CI) p-value
Drug-related mortality
On 1–4 weeks 0.60 (–0.76 to 1.95) 0.1327 0.61 (–0.76 to 1.98) 0.1387
On rest 0 (reference) 0 (reference)
Off 1–4 weeks 1.43 (0.16 to 2.69) 1.45 (0.17 to 2.73)
Off rest 0.35 (–0.32 to 1.02) 0.36 (–0.34 to 1.05)
On 1–4 weeks Methadone 0 (reference) 0.8816 0 (reference) 0.8928
Buprenorphine –0.94 (–3.62 to 1.73) 0.4891 –0.87 (–3.56 to 1.81) 0.5242
On rest (reference) Methadone 0 (reference) 0 (reference)
Buprenorphine –0.15 (–1.09 to 0.79) 0.7487 –0.16 (–1.12 to 0.80) 0.7438
Off 1–4 weeks Methadone 0 (reference) 0 (reference)
Buprenorphine 0.27 (–2.16 to 2.71) 0.8252 0.36 (–2.10 to 2.82) 0.7742
Off rest Methadone 0 (reference) 0 (reference)
Buprenorphine –0.51 (–1.62 to 0.61) 0.3704 –0.46 (–1.60 to 0.68) 0.4281
RD, risk difference (deaths/100 person-years).
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Note
Main effect and interaction p-values (3 df) are shown in bold.
TABLE 12 Proportional hazard survival analyses of OST type and period on mortality
Period OST type
Unadjusted Adjusteda
HR (95% CI) p-value HR (95% CI) p-value
All-cause mortality
On 1–4 weeks 3.05 (2.21 to 4.20) < 0.0001 3.06 (2.21 to 4.25) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 8.62 (6.96 to 10.68) 9.49 (7.59 to 11.86)
Off rest 2.44 (1.99 to 3.00) 2.79 (2.26 to 3.44)
On 1–4 weeks Methadone 1 (reference) < 0.0001 1 (reference) 0.0002
Buprenorphine 0.03 (0.01 to 0.12) < 0.0001 0.04 (0.01 to 0.15) < 0.0001
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.25 (0.16 to 0.39) < 0.0001 0.25 (0.15 to 0.39) < 0.0001
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.05 (0.03 to 0.09) < 0.0001 0.07 (0.04 to 0.12) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.21 (0.14 to 0.29) < 0.0001 0.21 (0.15 to 0.30) < 0.0001
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We also considered whether or not clustering by patient biased the standard errors (SEs) used in standard
analyses. There was some evidence of inflated SEs compared with standard Poisson analyses, but the changes
were minor (Table 13). These analyses also changed IRR estimates, but, again, the changes were minor.
TABLE 12 Proportional hazard survival analyses of OST type and period on mortality (continued )
Period OST type
Unadjusted Adjusteda
HR (95% CI) p-value HR (95% CI) p-value
Drug-related mortality
On 1–4 weeks 3.09 (1.40 to 6.83) < 0.0001 2.94 (1.32 to 6.59) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 6.05 (3.32 to 11.03) 5.98 (3.23 to 11.07)
Off rest 2.27 (1.36 to 3.78) 2.27 (1.35 to 3.83)
On 1–4 weeks Methadone 1 (reference) 0.1705 1 (reference) 0.1552
Buprenorphine 0.27 (0.03 to 2.18) 0.2178 0.27 (0.03 to 2.23) 0.2248
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.57 (0.20 to 1.66) 0.3064 0.57 (0.19 to 1.65) 0.2973
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 1.49 (0.58 to 3.87) 0.4101 1.62 (0.63 to 4.19) 0.3207
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.39 (0.16 to 0.96) 0.0403 0.42 (0.17 to 1.04) 0.0613
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Note
Main effect and interaction p-values (3 df) are shown in bold.
TABLE 13 Mixed-effects Poisson regression analyses of OST type and period on mortality
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
All-cause mortality
On 1–4 weeks 2.60 (1.85 to 3.64) < 0.0001 1.96 (1.37 to 2.80) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 10.51 (8.29 to 13.32) 9.42 (7.42 to 11.95)
Off rest 3.03 (2.35 to 3.91) 3.25 (2.57 to 4.12)
On 1–4 weeks Methadone 1 (reference) 0.0026 1 (reference) 0.0022
Buprenorphine 0.09 (0.02 to 0.36) 0.0008 0.06 (0.01 to 0.27) 0.0002
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.44 (0.26 to 0.75) 0.0025 0.27 (0.16 to 0.47) < 0.0001
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.14 (0.08 to 0.24) < 0.0001 0.07 (0.04 to 0.13) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.36 (0.24 to 0.55) < 0.0001 0.16 (0.10 to 0.25) < 0.0001
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In addition, we analysed subsets of data relating to either the first or the last episode. Any differences
between these two sets of results might indicate a cumulative effect of repeated treatment on the risk
of death. As the number of episodes increase, the first 4 weeks after treatment may be associated with
an increased risk of ACM (Tables 14 and 15).
TABLE 13 Mixed-effects Poisson regression analyses of OST type and period on mortality (continued )
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
Drug-related mortality
On 1–4 weeks 3.21 (1.44 to 7.17) < 0.0001 3.04 (1.31 to 7.06) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 6.59 (3.51 to 12.36) 7.05 (3.64 to 13.68)
Off rest 2.42 (1.40 to 4.20) 2.87 (1.53 to 5.40)
On 1–4 weeks Methadone 1 (reference) 0.2612 1 (reference) 0.1687
Buprenorphine 0.26 (0.03 to 2.11) 0.2058 0.29 (0.03 to 2.58) 0.2681
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.58 (0.19 to 1.77) 0.3395 0.69 (0.20 to 2.43) 0.5659
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 1.27 (0.47 to 3.38) 0.6369 1.62 (0.56 to 4.72) 0.3776
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.38 (0.16 to 0.95) 0.0390 0.40 (0.14 to 1.13) 0.0836
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Note
Main effect and interaction p-values (3 df) are shown in bold.
TABLE 14 Poisson analyses of mortality using the last episode for each patient
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
All-cause mortality
On 1–4 weeks 4.87 (3.54 to 6.69) < 0.0001 3.98 (2.88 to 5.51) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 19.57 (15.84 to 24.18) 17.31 (13.90 to 21.57)
Off rest 2.82 (2.30 to 3.45) 2.91 (2.36 to 3.59)
On 1–4 weeks Methadone 1 (reference) 0.0021 1 (reference) 0.0040
Buprenorphine 0.13 (0.03 to 0.52) 0.0041 0.09 (0.02 to 0.37) 0.0008
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.68 (0.43 to 1.06) 0.0893 0.43 (0.27 to 0.67) 0.0002
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.24 (0.14 to 0.40) < 0.0001 0.13 (0.08 to 0.22) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.62 (0.44 to 0.87) 0.0055 0.27 (0.19 to 0.39) < 0.0001
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TABLE 14 Poisson analyses of mortality using the last episode for each patient (continued )
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
Drug-related mortality
On 1–4 weeks 4.90 (2.23 to 10.79) < 0.0001 4.41 (1.98 to 9.80) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 12.22 (6.73 to 22.19) 10.58 (5.72 to 19.57)
Off rest 2.77 (1.67 to 4.59) 2.44 (1.44 to 4.14)
On 1–4 weeks Methadone 1 (reference) 0.1848 1 (reference) 0.1725
Buprenorphine 0.32 (0.04 to 2.61) 0.2887 0.35 (0.04 to 2.82) 0.3211
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.66 (0.23 to 1.90) 0.4407 0.64 (0.22 to 1.86) 0.4089
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 1.53 (0.60 to 3.88) 0.3684 1.67 (0.65 to 4.33) 0.2869
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.40 (0.17 to 0.96) 0.0411 0.43 (0.17 to 1.06) 0.0667
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Note
Main effect and interaction p-values (3 df) are shown in bold.
TABLE 15 Poisson analyses of mortality using the first episode for each patient
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
All-cause mortality
On 1–4 weeks 3.94 (2.64 to 5.87) < 0.0001 3.03 (2.01 to 4.56) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 12.69 (9.77 to 16.49) 10.66 (8.12 to 14.00)
Off rest 2.01 (1.54 to 2.60) 2.10 (1.60 to 2.75)
On 1–4 weeks Methadone 1 (reference) 0.0103 1 (reference) 0.0473
Buprenorphine 0.10 (0.01 to 0.71) 0.0215 0.07 (0.01 to 0.49) 0.0080
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.55 (0.30 to 0.99) 0.0477 0.29 (0.16 to 0.53) 0.0001
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.17 (0.08 to 0.37) < 0.0001 0.09 (0.04 to 0.19) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.66 (0.41 to 1.05) 0.0817 0.26 (0.16 to 0.42) < 0.0001
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Finally, we analysed ACM using different gaps in patient prescription histories to indicate a new treatment
episode. Decreasing the gap from 28 days in main analyses increased the number of episodes but also
increased the number of patients (Table 16). This was a result of treatment durations being shortened,
thereby increasing the chance that only one medication was prescribed. Conversely, increasing the gap
decreased the number of episodes and patients. The interaction effects were relatively robust to changes
in the definition of episodes with changes in effect sizes restricted to the treatment period main effect.
Summary
All analyses showed an increased risk of mortality in the first 4 weeks of treatment and the first 4 weeks
after treatment ceased, compared with after 4 weeks on treatment. These results are consistent with other
reports.53,64 Overall, mortality rates were higher during off treatment than during on treatment.30,64–66
All analyses for ACM and IPW analyses for DRP showed the presence of an interaction with OST type,
suggesting that the association in the first 4 weeks of treatments was more pronounced with methadone
than with buprenorphine. These results are consistent with a recent Australian study.53 However, although
we found a similar difference in risk for the remainder of time on treatment, that study found no differences
between methadone and buprenorphine. Our IRRs comparing buprenorphine with methadone for on- and
off-treatment periods are consistent with pooled estimates from a recent systematic review.64
The presence of an OST type by period interaction only in IPW for DRP may reflect the reduced power
associated with only 87 deaths. Although this may be an indication of under-reporting of DRP in causes of
death, the availability of such information for only 50% of patients within CPRD at the time of this study
was a major contributory factor to the reduction in power.
TABLE 15 Poisson analyses of mortality using the first episode for each patient (continued )
Period OST type
Unadjusted Adjusteda
IRR (95% CI) p-value IRR (95% CI) p-value
Drug-related mortality
On 1–4 weeks 4.73 (1.53 to 14.67) < 0.0001 3.90 (1.24 to 12.26) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 11.36 (5.01 to 25.75) 8.37 (3.61 to 19.42)
Off rest 2.69 (1.29 to 5.63) 2.01 (0.94 to 4.31)
On 1–4 weeks Methadone 1 (reference) 0.8840 1 (reference) 0.9537
Buprenorphine 0.73 (0.08 to 7.02) 0.7852 0.82 (0.08 to 8.06) 0.8679
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 1.29 (0.35 to 4.78) 0.6993 1.33 (0.35 to 5.04) 0.6721
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.73 (0.19 to 2.77) 0.6472 0.90 (0.23 to 3.53) 0.8851
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.66 (0.21 to 2.02) 0.4635 0.83 (0.26 to 2.63) 0.7479
a Adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type.
Note
Analyses based on 362 all-cause and 44 drug-related deaths.
Main effect and interaction p-values (3 df) are shown in bold.
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As previously reported,15–17,25,53 we found increased mortality risks immediately following the cessation
of treatment, but, in comparing different OST types, there were some differences. Whereas our data
suggested lower risks for buprenorphine with ACM but not with DRP, by contrast, the Australian study
reported a lower risk for methadone with DRP during the first 4 weeks following cessation.53
It is likely that the differences during treatment cessation after the first 4 weeks are indicative of residual
confounding or confounding by indication. Owing to the half-lives of OST medications, any direct
pharmacological effects of either medication are likely to be small.7 However, there may be indirect effects,
such as reduced opioid tolerance, with consequences for any relapse to drug abuse.36 Whether methadone
and buprenorphine treatment differ in these respects is unclear. In addition, one would expect any differences
in medication to diminish with time. Although this was observed for ACM, with differences halving compared
with the first 4 weeks, such a change was not observed for DRP.
Various sensitivity analyses involving different analysis techniques and different subsets of data did not
change these conclusions. Although propensity score and IV methods are well-established techniques,
we also explore modifications to the SCCS methods in Chapter 8.
It should be noted that we lacked information about patients’ illicit drug use during their treatment.
It is possible that some patients resorted to this to overcome withdrawal symptoms, potentially increasing
mortality. Another limitation was the use of naloxone, which may have reduced overdose deaths.
TABLE 16 Poisson analyses of ACM with episodes defined with 7- or 56-day prescription gap
Period OST type
7 days 56 days
IRR (95% CI) p-value IRR (95% CI) p-value
On 1–4 weeks 2.05 (1.53 to 2.74) < 0.0001 3.76 (2.66 to 5.32) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 5.87 (4.72 to 7.31) 15.00 (12.06 to 18.66)
Off rest 2.82 (2.29 to 3.46) 2.86 (2.32 to 3.52)
On 1–4 weeks Methadone 1 (reference) < 0.0001 1 (reference) 0.0029
Buprenorphine 0.06 (0.02 to 0.16) < 0.0001 0.03 (0.00 to 0.21) 0.0005
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.30 (0.19 to 0.48) < 0.0001 0.24 (0.15 to 0.38) < 0.0001
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.08 (0.05 to 0.13) < 0.0001 0.08 (0.05 to 0.14) < 0.0001
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.23 (0.17 to 0.33) < 0.0001 0.21 (0.15 to 0.31) < 0.0001
Episodes; patients; deaths 56,058; 11,590; 617 19,277; 10,706; 573
Note
Analyses adjusted for gender, age, year, comorbidity, region and, where applicable, treatment period and OST type. Main
effect and interaction p-values (3 df) are shown in bold. Main analyses were based on > 28-day gap in patient prescription
histories, leading to 26,546 episodes, 11,033 patients and 587 deaths.
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Chapter 6 Co-prescription of benzodiazepines,
z-drugs and gabapentinoids with opiate substitution
treatment
In Chapter 4, we reported that about 50% of patients received benzodiazepines, z-drugs or gabapentinoidsin addition to OST. Given that current treatment guidelines discourage this practice,34,35 in this chapter on
WP 3 we will explore the effects on mortality of co-prescription.
Aims and objectives
Our main aim was to explore the effects of co-prescription on mortality risk. For comparison with a recent
study,31 we also analysed deaths from non-drug related causes in addition to ACM and DRP. Given the
strong effects on OST type and treatment period noted in WP 2, we also investigated whether or not the
co-prescription effects varied with these OST factors.
Data set for the main analyses
There were 29,540 OST episodes involving methadone or buprenorphine (see Figure 2). As our primary
aim was not to compare OST medications, we included partial episodes of methadone and buprenorphine
to increase the power of comparisons. These episodes related to 12,118 patients, of whom 42% received
benzodiazepine co-prescription, 20% received z-drug co-prescription and 8% received gabapentinoid
co-prescription. In 36,126 person-years of follow-up there were 657 ACM deaths.
Key findings from the submitted paper
The results for co-prescription of the three medications with OST are summarised in Table 17. All
co-prescribed medications were related to ACM and DRP such that co-prescription increased the risk
of mortality. There was evidence of a dose–response relationship for benzodiazepines with DRP but not
with ACM. Only gabapentinoids were associated with an increase in risk of non-drug-related mortality.
TABLE 17 Summary of associations between co-prescription with OST and mortality
Co-prescribed
Mortality
All cause Drug related Non-drug related
Benzodiazepines 1.16 2.02 (D)
z-drugs 1.83 3.31
Gabapentinoids 1.99 1.60 2.15
D, dose-related association. Other associations relate to on/off treatment.
Note
Effect sizes are IRRs. Blank cells indicate no association.
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Concurrent prescription of benzodiazepine was associated with an approximate doubling of the duration
of methadone treatment (adjusted mean duration of treatment episode 444 days compared with 288 days).
In analyses considering this increased duration of OST, the overall adverse effect on mortality risk was still
apparent (DRP with benzodiazepine concurrent prescription compared with patients with no concurrent
exposure; adjusted IRR 4.04, 95% CI 2.35 to 6.95).
Sensitivity analyses were performed using survival analysis and Poisson regression excluding the first OST
episode. Those results were consistent with those of the main analyses.
Interactions with opiate substitution treatment type and period
In the previous chapter, we found OST type to interact with a number of factors, including OST period,
age and comorbidity. Consequently, it seemed plausible that OST type may also interact with these
three co-prescribed medications. In addition, there were key questions concerning the timing of these
medications relating to whether or not the exposure was concurrent with OST. A priori, one might have
expected a greater effect concurrent with OST than during periods after OST has ceased. These issues
were explored using an interaction with OST period.
The results from these analyses are summarised in Table 18. To take account of the possibility that OST
period with four categories may be underpowered to detect concurrent specific effects, interactions
were also fitted using a two-level factor reflecting on and off OST. Overall, there was no evidence of
any interactions. The strongest evidence was for gabapentinoids with ACM. These data suggested
that gabapentinoids had an adverse association with mortality for methadone only, with no effect for
buprenorphine episodes. The interaction with period suggested an adverse effect only for the period of
treatment after the first 4 weeks and the first 4 weeks after treatment cessation. However, given the
number of statistical tests being employed, both of these results may be chance events.
TABLE 18 Interactions between co-prescribed medications and OST type or period
Medication
All cause Drug related Non-drug related
Type Period4 Period2 Type Period4 Period2 Type Period4 Period2
B on/off 0.7437 0.4499 0.5014 0.2006 0.2781 0.5665 0.9805 0.7949 0.5811
B low/high 0.1051 0.3771 0.2885 0.6201 0.2054 0.2337 0.5236 0.9148 0.5807
B linear 0.3009 0.3954 0.2822 0.1505 0.4055 0.5145 0.7532 0.6707 0.4324
Z on/off 0.4284 0.3633 0.2646 0.1268 0.4070 0.7308 0.6749 0.6550 0.3995
Z low/high 0.5722 0.1932 0.0648 0.2565 0.8235 0.9106 0.8477 0.2834 0.0763
Z linear 0.6374 0.1633 0.0822 0.1765 0.6945 0.7636 0.7826 0.3953 0.1031
G on/off 0.0059 0.0022 0.0419 0.0979 0.0795 0.1412 0.1807 0.6647
B, benzodiazepines; G, gabapentinoids; Z, z-drugs.
Notes
OST type was coded as methadone or buprenorphine. OST period was coded as either four groups (on 1–4 weeks, on rest,
off 1–4 weeks, off rest) or two groups (on, off).
Co-prescribed medications were modelled as on or off treatment with benzodiazepines and z-drugs were also analysed
where on treatment was split as low or high (within or above recommended doses).
The interaction for gabapentinoids and OST type could not be fitted for DRP because zero deaths were observed for
buprenorphine with gabapentinoid on treatment.
Analyses were adjusted for gender, age, year, comorbidity, region and, where applicable, OST type, OST period,
benzodiazepine, z-drug and gabapentinoid exposure.
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Co-prescription and the opiate substitution treatment
type × period interaction
Given that the OST type propensity score included a contribution from co-prescription, it was expected
that further adjustment for co-prescription would have little effect on this interaction. In addition, given
the similarity in IPW analyses with standard Poisson regression for ACM, it might also be expected that
these results would not be materially affected. These assumptions were verified in Table 19.
Summary
We found that co-prescription of benzodiazepines was associated with an increased risk of DRP. This was
consistent with most studies,26,28–30 although one found no association.31 Although we also found weak
associations with ACM, the evidence from other studies was more equivocal.26,31,67 We found z-drugs and
gabapentinoids to be associated with DRP, as found in one other study.31 For ACM, our positive association
was inconsistent with the only other study involving OST patients,31 although there was some evidence of
increased risk for these medications for opioid users.32,33 Whether the association with gabapentinoids is a
reflection of the medication itself or confounding by the illnesses it is trying to treat remains unclear.
Our results have implications for clinical practice for OST. With over one-quarter of OST patients receiving
benzodiazepines, the increased mortality risk associated with their co-prescription suggests that this may
include an avoidable number of risks if suitable alternative treatment can be found. For instance, if they
have been prescribed for psychological stress, other means of support may be available. For z-drugs, similar
drug-related mortality risks and higher ACM risks were observed in this study, suggesting that similar
warnings concerning co-prescription are warranted for this class of medications. With the co-prescription of
gabapentinoids being relatively rare in this study, and with few other studies examining these medications,
the implications for policy are less clear for gabapentinoids.
TABLE 19 Poisson regression analyses of mortality adjusting for co-prescription
Period OST type
All-cause mortalitya Drug-related mortalitya
IRR (95% CI) p-value IRR (95% CI) p-value
On 1–4 weeks 3.35 (2.44 to 4.60) < 0.0001 3.24 (1.54 to 6.79) < 0.0001
On rest 1 (reference) 1 (reference)
Off 1–4 weeks 11.82 (9.58 to 14.57) 7.36 (4.22 to 12.83)
Off rest 3.43 (2.82 to 4.17) 3.33 (2.12 to 5.25)
On 1–4 weeks Methadone 1 (reference) 0.0007 1 (reference) 0.0799
Buprenorphine 0.04 (0.01 to 0.18) < 0.0001 0.23 (0.03 to 1.83) 0.1643
On rest (reference) Methadone 1 (reference) 1 (reference)
Buprenorphine 0.25 (0.16 to 0.39) < 0.0001 0.37 (0.13 to 1.07) 0.0661
Off 1–4 weeks Methadone 1 (reference) 1 (reference)
Buprenorphine 0.09 (0.06 to 0.15) < 0.0001 1.49 (0.62 to 3.59) 0.3700
Off rest Methadone 1 (reference) 1 (reference)
Buprenorphine 0.24 (0.17 to 0.33) < 0.0001 0.43 (0.21 to 0.90) 0.0256
a Adjusted for gender, age, year, comorbidity, region, benzodiazepine, z-drug, gabapentinoids and, where applicable,
treatment period and OST type.
Note
Main effect and interaction p-values (3 df) are shown in bold.
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Chapter 7 Initiation and cessation of opiate
substitution treatment
Initiation and cessation of OST are key periods in the treatment of opioid abuse when risks of overdoseand withdrawal need to be minimised. Current clinical guidance recommends a low initial dose with
steady increases to a maintenance level and gradual reduction in dose leading to a low final dose.7,36 As
adherence to these guidelines was poor, as seen in Chapter 4, in this chapter on WP 4, we explore whether
or not these deviations had any adverse impact on mortality.
Aims and objectives
In this WP, we planned to investigate whether or not the risk of mortality is reduced with:
l supervised consumption of OST medication
l low initial doses with increasing doses over the first 28 days of treatment
l low final doses with decreasing doses over the last 28 days of treatment.
Our primary aims were to explore the associations of these factors with mortality during the first 28 days
of treatment for initiation and the first 28 days following the end of treatment for cessation. Analyses
would explore whether or not these associations differed by OST type.
In addition, we explored whether or not adherence to current guidelines for initiation and cessation varied
over time.
Data set
As we were concerned with only the first or last 28 days of a treatment episode, we restricted episodes to
those involving only methadone or buprenorphine during these times. The data used in these analyses
related to 11,289 patients and 26,544 episodes (see Figure 2). However, owing to differing criteria for
initiation or cessation (see Initiation of opiate substitution treatment and Cessation of opiate substitution
treatment), and to some episodes being only partially included within the study period (and hence the
initiation or cessation periods may be excluded), not all of these data were used in any one analysis.
Supervised consumption
From the supplied CPRD data, it was possible to identify supervised consumption only from the free text
associated with each prescription. Searches revealed 4071 prescriptions, with 3831 using the phrase
‘supervised administration’ and 240 using ‘supervised consumption’. These related to 184 patients and
were all for methadone. Searches involving likely spelling mistakes or abbreviations discovered no
additional prescriptions.
We requested CPRD to search its databases, including information not normally released. It identified
16,750 prescriptions for 591 patients for the whole database (not just our data set) covering the period
1987 to March 2015.
Overall, we concluded that the prevalence of supervised consumption was seriously under-reported and
that using the available data would be underpowered to address research objectives as a result of both the
low observed prevalence and the dilution of effects as a result of misclassification.
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Initiation of opiate substitution treatment
We characterised the initiation of treatment using two measures: the starting dose and the change in dose
during the first 28 days. Episodes were included in the analyses where only one medication was prescribed
in the first 28 days, there was valid dose information for at least part of this time and some part of the
first 28 days of treatment occurred between the study dates. This led to 10,817 patients providing data for
25,246 episodes.
Cessation of opiate substitution treatment
Similarly, ending dose and the change in dose over the last 28 days were used to describe cessation.
Treatment could end by planned cessation, dropout or death. Episodes were included in the analyses
where only one medication was prescribed during the last 28 days, there was valid dose information
for at least part of this time, the duration exceeded 90 days and some part of the first 28 days following
cessation occurred between the study dates. It should be noted that episodes were excluded where
treatment had not ceased but data were unavailable owing to loss to follow-up. This led to 6491 patients
providing data for 10,811 episodes.
Analyses
We investigated the impact of initiation and cessation characteristics on ACM and DRP.
Initiation and cessation characteristics were analysed both as linear covariates and as categorical factors to
allow for non-linear effects. Methadone doses for the linear covariates were divided by five to achieve a
dose more equivalent to buprenorphine. For starting/ending doses, a four-level factor was derived, with the
lowest dose category defined as ≤ 20 mg (≤ 4 mg) of methadone (buprenorphine) and increasing by 20 mg
(4 mg) per category until the highest dose category of > 60 mg (> 12 mg). For change in dose, this was
categorised as binary variables, with any increase in dose for initiation or any decrease in dose for cessation
being expected to be more favourable in terms of mortality than no increase or decrease, respectively.
Although standard adjustment was made for gender, age, year, comorbidity and UK region, we also
adjusted for OST type as an additional model. The inclusion of OST type allowed proportional effects
(parallel effects on a log scale) to be investigated. Previous interactions with OST type have been observed
in WP 2 and it seemed advisable also to consider the possibility that initiation and cessation characteristics
might interact with OST type.
Adherence to the guidelines7 was based on low starting or ending doses and optimal changes in dose
during the first 28 days after either the start or the end of treatment.
Results
Initiation and cessation characteristics
The results from the linear growth models are shown in Table 20. Characteristics differed between
methadone and buprenorphine. Both starting and ending doses for methadone episodes were evenly
distributed across the four categories, with 21% to 27% of episodes being associated with the lowest
dose. By contrast, for buprenorphine, ≈50% of episodes started or ended with the lowest dose category.
Most episodes showed little evidence of any change in dose, with only about 30% of episodes showing
increases during initiation or decreases during cessation. The exception appeared to be the change in dose
for methadone episodes during the first 28 days. Here, 68% showed some increase in dose, but, as the
mean suggests, the overall increases were small.
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Initiation and mortality
Only about 7% of the deaths available in WP 3 were valid for these analyses. This led to 48 ACM and
eight DRP deaths (Table 21).
Higher starting doses were associated with an increased risk of ACM. Unadjusted results suggested a 7%
increase in risk for every 5-mg increase in the starting dose of methadone (1-mg increase in buprenorphine)
(HR 1.07, 95% CI 1.03 to 1.10). Adjustment for confounders and then OST type attenuated the results,
but the association remained (HR 1.04, 95% CI 1.00 to 1.09). Categorising the starting dose may suggest
that the biggest change in risk was exceeding low doses, although the CIs were too wide to obtain robust
statistical evidence. There was some evidence that increasing the dose over the first 28 days also appeared
to be beneficial, reducing mortality risks by 5% (HR 0.95, 95% CI 0.90 to 1.00).
An analysis of DRP produced similar results to that of ACM in terms of point estimates, with a 3% increase
in risk being associated with the linear starting dose effect and a 7% reduction in risk for the linear change
in dose effect. However, with only eight deaths, the CIs were wide and the statistical evidence weak.
There was no evidence that these effects varied between patients prescribed methadone and those
prescribed buprenorphine (interaction p > 0.39).
Cessation and mortality
Only about 11% of the deaths available in WP 3 were valid for these analyses. This led to 75 ACM and
12 DRP deaths (Table 22).
For ACM, higher ending doses were associated with increased risk. Similar to initiation, adjustment
attenuated linear effect sizes by about 50%. With full adjustment, the results were perhaps underpowered,
but suggested a 3% increase in mortality risk associated with every 5-mg increase in ending dose of
methadone (1-mg increase for buprenorphine) (HR 1.03, 95% CI 0.99 to 1.07). As for initiation, the biggest
change in risk was to exceed the low dose. For DRP, adjustment amplified effect sizes, almost trebling
the linear effect size. Here, there was a 17% increase in risk associated with every 5-mg methadone
TABLE 20 Starting/ending doses and changes in dose during the first and last 28 days of episodes
Initiation (first 28 days) Cessation (last 28 days)
Daily dose Methadone Buprenorphine Daily dose Methadone Buprenorphine
Lowesta 3564 (20.75) 3879 (47.27) Lowesta 2258 (27.79) 1407 (51.31)
6028 (35.10) 1701 (20.73) 1969 (24.24) 726 (26.48)
4054 (23.61) 1488 (18.13) 1695 (20.86) 252 (9.19)
Highest 3527 (20.54) 1138 (13.87) Highest 2202 (27.10) 357 (13.02)
Mean (SD) 42.56 (30.39) 6.08 (6.51) 43.12 (34.55) 5.57 (6.04)
n (episodes) 17,173 8206 8124 2742
Change in dose
No increase 5494 (31.99) 5044 (61.47) No decrease 5674 (69.84) 1934 (70.53)
Any increase 11,679 (68.01) 3162 (38.53) Any decrease 2450 (30.16) 808 (29.47)
Mean (SD) 1.20 (23.29) –0.28 (5.25) 2.87 (27.89) 0.25 (4.42)
n (episodes) 17,173 8206 8124 2742
a Daily dose categories were lowest ≤ 20 (≤ 4), > 20–40 (> 4–8), > 40–60 (> 8–12) and highest > 60mg (> 12mg) of
methadone (buprenorphine).
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TABLE 21 Cox regression results for initiation and the first 28 days of treatment
Dose Category Deaths PY
Unadjusted Adjusteda Adjusteda+OST type
MR HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
ACM
Starting Linearb 1.07 (1.03 to 1.10) 0.0001 1.05 (1.02 to 1.09) 0.0044 1.04 (1.00 to 1.09) 0.0413
Starting Lowestc 13 434 3.00 1 (reference) 0.0795 1 (reference) 0.2168 1 (reference) 0.5574
15 499 3.01 2.31 (0.99 to 5.34) 1.76 (0.65 to 4.76) 0.76 (0.25 to 2.28)
9 360 2.50 2.27 (0.87 to 5.92) 3.03 (0.99 to 9.21) 1.56 (0.48 to 5.08)
Highest 11 297 3.70 3.03 (1.27 to 7.26) 2.39 (0.86 to 6.69) 1.32 (0.45 to 3.90)
Change Linearb 0.94 (0.89 to 0.99) 0.0195 0.94 (0.89 to 0.99) 0.0238 0.95 (0.90 to 1.00) 0.0655
Change No increase 14 650 2.15 0.54 (0.28 to 1.02) 0.0565 0.69 (0.33 to 1.45) 0.3249 1.04 (0.46 to 2.36) 0.9279
Any increase 34 939 3.62 1 (reference) 1 (reference) 1 (reference)
Drug-related mortality
Starting Linearb 1.02 (0.91 to 1.15) 0.6979 1.04 (0.88 to 1.23) 0.6227 1.03 (0.86 to 1.23) 0.7421
Starting Lowestc 2 278 0.72 1 (reference) 0.8202 1 (reference) 0.4125 1 (reference) 0.3297
3 296 1.01 1.33 (0.20 to 8.87) 0.21 (0.01 to 6.58) 0.02 (0.00 to 3.62)
2 215 0.93 2.72 (0.34 to 22.11) 3.52 (0.21 to 58.18) 2.16 (0.13 to 34.79)
Highest 1 148 0.67 1.73 (0.13 to 23.07) 0.97 (0.03 to 30.81) 0.32 (0.01 to 12.88)
Change Linearb 1.00 (0.81 to 1.25) 0.9902 0.97 (0.70 to 1.34) 0.8436 0.93 (0.68 to 1.27) 0.6436
Change No increase 2 412 0.49 0.50 (0.08 to 3.01) 0.4479 0.98 (0.12 to 8.35) 0.9873 1.69 (0.18 to 15.59) 0.6447
Any increase 6 525 1.14 1 (reference) 1 (reference) 1 (reference)
HR, hazard ratio implicitly adjusted for age; MR, mortality rate (deaths/100 person years); PY person-years of follow-up.
a Adjusted for gender, calendar year, comorbidity score and region.
b Effect sizes are per 5-mg increase in methadone dose (1-mg increase in buprenorphine); linear effects relate to a log scale.
c Daily dose categories were lowest ≤ 20 (≤ 4), > 20–40 (> 4–8), > 40–60 (> 8–12) and highest > 60mg (> 12mg) of methadone (buprenorphine).
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TABLE 22 Cox regression results for cessation and the first 28 days after the end of treatment
Dose Category Deaths PY
Unadjusted Adjusteda Adjusteda+OST type
MR HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
ACM
Ending Linearb 1.06 (1.03 to 1.09) 0.0001 1.04 (1.01 to 1.08) 0.0158 1.03 (0.99 to 1.07) 0.0926
Ending Lowestc 8 273 2.93 1 (reference) 0.0005 1 (reference) 0.0262 1 (reference) 0.1041
24 196 12.26 4.49 (1.94 to 10.42) 3.41 (1.41 to 8.26) 2.94 (1.21 to 7.13)
16 141 11.38 4.91 (1.98 to 12.21) 3.73 (1.44 to 9.65) 2.79 (1.06 to 7.35)
Highest 27 183 14.77 5.72 (2.46 to 13.30) 3.32 (1.35 to 8.17) 2.43 (0.97 to 6.10)
Change Linearb 1.00 (0.95 to 1.05) 0.9607 0.99 (0.93 to 1.05) 0.7257 0.99 (0.94 to 1.05) 0.7338
Change No decrease 61 552 11.06 1.34 (0.71 to 2.53) 0.3674 1.35 (0.69 to 2.66) 0.3824 1.47 (0.73 to 2.95)d 0.2790
Any decrease 14 240 5.83 1 (reference) 1 (reference) 1 (reference)
Drug-related mortality
Ending Linearb 1.06 (0.97 to 1.16) 0.1833 1.08 (0.98 to 1.19) 0.1227 1.17 (1.02 to 1.33) 0.0209
Ending Lowestc 3 166 1.81 1 (reference) 0.8374 1 (reference) 0.8032 1 (reference) 0.2426
3 118 2.53 1.40 (0.27 to 7.33) 1.57 (0.20 to 12.14) 1.41 (0.16 to 12.28)
3 84 3.57 2.05 (0.38 to 11.04) 1.80 (0.32 to 10.21) 4.24 (0.63 to 28.66)
Highest 3 87 3.43 1.86 (0.36 to 9.68) 2.42 (0.39 to 14.94) 11.59 (0.93 to 144)
Change Linearb 1.00 (0.86 to 1.16) 0.9881 1.01 (0.85 to 1.21) 0.8935 1.03 (0.84 to 1.25) 0.8044
Change No decrease 7 310 2.26 0.72 (0.22 to 2.40) 0.5932 0.69 (0.19 to 2.55) 0.5802 0.88 (0.22 to 3.52) 0.8555
Any decrease 5 146 3.43 1 (reference) 1 (reference) 1 (reference)
HR, hazard ratio implicitly adjusted for age; MR, mortality rate (deaths/100 person-years); PY, person-years of follow-up.
a Adjusted for gender, calendar year, comorbidity score and region.
b Effect sizes are per 5-mg increase in methadone dose (1-mg increase in buprenorphine); linear effects relate to a log scale.
c Daily dose categories were lowest ≤ 20 (≤ 4), > 20–40 (> 4–8), > 40–60 (> 8–12) and highest > 60mg (> 12mg) of methadone (buprenorphine).
d Interaction with OST type (p = 0.022), HR no decrease for methadone 2.00 (95% CI 0.90 to 4.42), for buprenorphine 0.26 (95% CI 0.05 to 1.24).
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(1-mg buprenorphine) increase in ending dose (HR 1.17, 95% CI 1.02 to 1.33). Unlike ACM, the biggest
change in risk may be associated with exceeding medium doses.
There was no evidence that changing dose over the last 28 days had any effect on mortality risks.
There was some evidence that the change in dose effect varied with OST type for ACM (interaction
p = 0.022). Whereas no decrease in dose appeared to be associated with an increase risk by 100% for
methadone (p = 0.088), there was a 75% reduction in risk for buprenorphine (p = 0.091) compared with
any decrease.
Trends in adherence for initiation and cessation
Prior to the guidelines in 2007,7 there was declining adherence or no change in adherence (Table 23).
In particular, starting and ending doses and change in dose for methadone during cessation showed
evidence of declining adherence. After the guidelines, this decline was generally halted for initiation
starting doses and may be improving for most cessation characteristics.
Summary
Evidence that OST initiation and cessation followed current guidelines has historically been poor. Although
there was evidence that adherence is improving, evidence of planned titration and discharge remains
low. There was considerable variability in initiation and cessation characteristics. This may reflect errors in
recorded or imputed daily doses, missing prescription data misclassifying one episode as two episodes or,
for initiation, accelerated detoxification.
The trend towards lower starting and ending doses being associated with lower risk of mortality was
found for ACM. For DRP, the same trends were observed but the evidence was weaker as result of the
lack of power associated with few deaths. This is consistent with other studies reporting the lowest
incidence of mortality among those starting on < 30mg/day methadone and those completing detoxification.68,69
We found weak evidence for a beneficial association on mortality risk for an increasing dose during the
first 28 days of treatment. Although our data did not exhibit large rapid increases in dose, one study has
reported an increased risk of mortality associated with too-rapid increases in methadone dose.68 There was
no evidence that changes in dose during cessation were associated with mortality. This may reflect that a
period of 28 days was too short to capture optimal changes in dose.
Although it was interesting that effect modification for change in dose with OST type for cessation
appeared to be present for ACM, the interaction was difficult to interpret and was probably a chance
event among the multiple comparisons being tested.
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TABLE 23 Trends in adherence to Department of Health and Social Care guidelines from 2001 to 2014
Year
Initiation [Total number of episodes (% adherence)] Cessation [Total number of episodes (% adherence)]
Starting dose Increase in dose Ending dose Decrease in dose
Methadone Buprenorphine Methadone Buprenorphine Methadone Buprenorphine Methadone Buprenorphine
2001 1235 (25.51) 318 (60.38) 1235 (68.02) 318 (36.16) 463 (32.18) 69 (66.67) 463 (37.80) 69 (30.43)
2002 1291 (24.09) 497 (46.68) 1291 (67.70) 497 (35.01) 500 (29.40) 120 (56.67) 500 (33.60) 120 (30.00)
2003 1389 (21.74) 637 (44.90) 1389 (69.26) 637 (41.44) 509 (25.93) 180 (54.44) 509 (28.09) 180 (30.56)
2004 1271 (21.32) 718 (38.86) 1271 (67.19) 718 (37.19) 653 (27.72) 215 (55.35) 653 (28.02) 215 (29.77)
2005 1152 (22.14) 737 (41.79) 1152 (67.97) 737 (37.04) 564 (25.35) 242 (47.93) 564 (26.06) 242 (28.93)
2006 1209 (19.35) 718 (39.69) 1209 (68.73) 718 (39.00) 588 (25.17) 233 (43.78) 588 (27.21) 233 (33.91)
2007 1175 (20.68) 695 (44.03) 1175 (68.85) 695 (40.14) 533 (25.52) 243 (44.86) 533 (25.70) 243 (33.74)
2008 1200 (20.42) 648 (43.06) 1200 (68.58) 648 (36.88) 548 (24.27) 237 (43.88) 548 (25.91) 237 (29.96)
2009 974 (16.94) 625 (51.04) 974 (68.89) 625 (37.44) 542 (25.46) 202 (48.02) 542 (29.34) 202 (24.75)
2010 1024 (17.58) 552 (50.00) 1024 (71.09) 552 (41.85) 464 (27.37) 199 (42.21) 464 (30.60) 199 (26.63)
2011 797 (15.68) 496 (52.62) 797 (64.62) 496 (40.12) 519 (25.43) 182 (51.65) 519 (31.79) 182 (29.67)
2012 717 (18.27) 517 (48.16) 717 (66.11) 517 (40.81) 491 (27.90) 222 (54.95) 491 (30.14) 222 (35.59)
2013 624 (17.31) 432 (39.81) 624 (65.87) 432 (35.65) 393 (24.68) 199 (53.27) 393 (27.23) 199 (28.64)
2014 299 (23.41) 236 (44.49) 299 (66.56) 236 (37.71) 229 (25.33) 96 (52.08) 229 (26.20) 96 (30.21)
Trends
2001–6 –0.061, 0.0002 –0.121, < 0.0001 0.003, 0.8416 0.015, 0.4874 –0.063, 0.0068 –0.156, 0.0002 –0.100, < 0.0001 0.025, 0.5648
2007–14 –0.021, 0.1576 0.002, 0.8808 –0.025, 0.0423 –0.004, 0.7914 0.007, 0.6688 0.066, 0.0041 0.019, 0.2671 0.000, 0.9946
Equality 0.0693 < 0.0001 0.1443 0.4692 0.0152 < 0.0001 < 0.0001 0.6185
Notes
Adherence was based on low doses for starting and ending doses. Trends are calculated by logistic regressions on the percentages adherent. The results are reported as the change in
log-odds per calendar year with the p-value. The trends are calculated pre (2001–6) and post guidelines (2007–14). The equality of these trends is reported as an interaction p-value.
Data for 1998–2000 were excluded because there were too few buprenorphine episodes.
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Chapter 8 Development of self-controlled case
series methods for opiate substitution treatment data
In this project we have attempted to use a number of methods to obtain more robust results. In thischapter, on WP 5, we describe the modification of two SCCS methods48,50 and the results comparing
these methods using simulations.
Aims and objectives
Self-controlled case series methods have been developed to study the adverse reactions to vaccinations.48,50
In these scenarios, treatment episodes consist of a series of very short exposures (the injections) at regular
intervals. This is in stark contrast to therapeutic data, where exposure times are variable and can last for
months and where the sequence of episodes is not predetermined and will vary both in frequency
and number.
In the context of OST data, there are two main problems. First, having a variable treatment period leads
to an open-ended risk period following the first 4 weeks of treatment. This period would need to be
estimated if death occurs during treatment. The equivalent open-ended period after treatment had ceased
for more than 4 weeks was not originally considered to raise major issues. Second, there were two main
types of treatment involving methadone or buprenorphine with their effects on mortality varying with the
treatment period.
The aims of this WP were to extend existing methods to cater for these additional characteristics of OST
data. We used simulations to verify that the modifications were robust and finally to apply the modified
methods to the real data relating to WP 2 to investigate the OST type × period interaction.
The implications of these facets of the OST data are discussed in the next section as we describe some of
features of the SCCS methods. Other characteristics of the OST data and their implications to SCCS
analyses are described in the report under submission.
Implications of the existing self-controlled case series methods for
opiate substitution treatment data
The two methods are referred to as the Farrington48 and Kuhnert50 methods, both of which are relevant
to censored data as arise in the study of mortality. Both methods analyse only cases using fixed-effects
Poisson regression clustering on patients. Using this technique has advantages in that the fixed effects
can adjust for all non-time-varying factors, whether or not observed, associated with the patient. Both
methods attempt to reconstruct the last episode, when death occurred, as if death had not occurred.
In the context of vaccination data, this is straightforward, as typically there is a single risk period for each
episode of fixed duration. Although the subsequent control period is technically open-ended, this is
catered for differently by the two methods. For the Kuhnert method, there is usually a known earliest
date for the next vaccination, whereas for the Farrington method there is usually a known date when
follow-up was planned to cease. These dates are used to set the end of the control period.
Differences between the two methods reflect the exclusion of cases and the derivation of pseudo-
individuals. For the Kuhnert method, patients who died after the earliest date for the next vaccination are
excluded but all included patients appear only once. By contrast, for the Farrington method, all cases are
included but copies of each patient’s data are generated to reflect unobserved scenarios in which each
observed treatment episode was the only episode to occur.
DOI: 10.3310/hsdr07030 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 3
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Steer et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
For the OST data, the open-ended treatment period was imputed using treatment duration data for
patients who survived. Imputations were based on matched patients receiving the same medication at a
similar time and of a similar age to those patients who died. For the open-ended period after treatment
ceased, a date 1 year after the last treatment ended was used for the Farrington method. For the Kuhnert
method, although 28 days was the observed minimum interval between treatment episodes, this interval
was too short to allow estimation of the open-ended period. Hence, a range of intervals from 35 to
56 days was tried.
The presence of two medications had consequences for estimating the type × period interaction. Because
only one episode and hence one medication was used for all patients in the Kuhnert method and all
pseudo-individuals in the Farrington method, 1 df was aliased between the interaction and the clustered
fixed effect. To overcome this, the open-ended off-treatment period was assumed to be equal for
methadone and buprenorphine.
Data set used in simulations
Data relating to 11,033 patients as used in WP 2 were also used in this WP, but instead of using the
observed deaths, simulated deaths were generated using the observed risks for covariates obtained from
WP 2 using Poisson regression. In all, 1000 simulated data sets were generated, producing results for both
methods under different scenarios.
Key findings from the submitted paper
Simulations suggested that the Farrington method, assuming a projected end to follow-up of 150 days
after the last treatment ended, produced estimated effects closest to the true values. For the Kuhnert
method, the shortest interval performed best, although the differences between 35 and 56 days were
small. This characteristic was important, as there may be insufficient numbers of death for shorter intervals
to allow the interactions to be modelled.
Using these modified methods with the observed data allowed comparisons with an alternative robust
method, IPW, as reported in WP 2.61 For ACM, these methods also showed evidence of a OST type × period
interaction, although stronger evidence came from the Farrington method, probably because of the greater
number of deaths that were valid for this method. There was perhaps some deviation from results reported
in WP 2 in that differences between methadone and buprenorphine were smaller and statistically equivalent
for the period following the first 4 weeks of treatment for the Farrington method (interaction IRR 1.04,
95% CI 0.55 to 1.94) and for the Kuhnert method (interaction IRR 2.34, 95% CI 0.56 to 9.84). At other times,
as reported in WP 2, buprenorphine was protective compared with methadone. For DRP, no evidence of an
interaction was found with either method, in contrast to results from IPW analyses. However, SEs were
large in these analyses, making the detection of any potential interaction effects difficult.
Summary
Simulations have suggested that modifications to the SCCS methods have produced robust results.
As a consequence, these methods can be applied not only to vaccination data but also to therapeutic
prescription-based data. This may be particularly helpful for databases that contain limited additional
information on patients’ histories, severity of symptoms and treatment quality. However, robust results
were achieved only with a relatively short intertreatment gap for the Farrington method and a very short
gap for the Kuhnert method, although, for the Kuhnert method, this was to be expected as this interval
should reflect the minimum gap between treatment episodes. The use of such constraints inevitably
reduced the number of analysed deaths. Applying the revised methods to the observed data on mortality
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and episodes of methadone and buprenorphine treatment reduced the number of deaths in the
constrained sample by about 10% for the Farrington method and about 30% for the Kuhnert method
compared with the original Poisson regressions reported in Chapter 5. The results suggested an OST
type × period interaction for ACM but were too underpowered to evaluate DRP.
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Chapter 9 Conclusions
This chapter considers the implications for clinical practice arising from the results of this study, a reviewof the potential limitations of this study and recommendations for future work.
Patient and public involvement
Our patient and public involvement (PPI) work demonstrates why we need to be very cautious in drawing
conclusions on which form of OST is safer and more likely to reduce mortality risk in the population
(see Appendix 3 for more details). Drug workers and people who use opioids highlighted that there may
be multiple reasons why people who choose or are prescribed buprenorphine are different from people
who choose or are prescribed methadone, in terms of stability, mood and use of heroin and other drugs
during treatment. For this reason, our PPI group were not surprised that fewer people died in the first
4 weeks of buprenorphine treatment than methadone treatment – even after adjustment for multiple
confounders (differences in patient and practice characteristics between patients on methadone and those
on buprenorphine). There was some, but not widespread, support for a trial that seeks to induct all patients
onto buprenorphine where patients did not express a strong preference for methadone. However, others
raised concerns over the probable need for additional psychological support and the potentially unintended
consequences of such a trial (in terms of patients withdrawing from treatment or moving services). The PPI
group confirmed that there is no clear and quick fix to reduce drug-related deaths in the population through
changing the way in which OST is delivered. More development is needed to establish an acceptable
intervention and trial of OST delivery (see Chapter 9, Future research).
Drug-related poisoning and all-cause mortality rates
The average annual ACM and DRP in our study, at 1.9% and 0.8%, respectively, were slightly higher than
in some earlier studies of mortality in cohorts obtained from community drug treatment agencies (0.34 per
100 person-years based on the NDTMS30,44), although our findings were consistent with recent systematic
review evidence.64 It is likely that the NDTMS population is a mix of opioid users who may not all be
receiving OST, in contrast to the CPRD population, which comprises people with opioid disorders in OST.
There may also be differences in morbidity between CPRD and NDTMS populations, but we lack consistent
data between the two systems to allow us to compare morbidity (see Future research).
Clinical implications and recommendations
Our data suggest that there was an increased risk of mortality during the first 4 weeks of treatment,
with lower risks being associated with buprenorphine treatment. Although this may suggest advantages in
prescribing buprenorphine during induction and switching to methadone later if necessary, our investigations
into such strategies showed only a low probability of reducing DRP.
The increased risk of ACM mortality following cessation of treatment may indicate poor retention in
treatment or the need for greater patient support when the impact of reduced opioid tolerance is
most acute. The lower risk for buprenorphine during this period may suggest benefits in switching to
buprenorphine during the final stages of treatment.
We identified particular groups of patients in our data, namely those who were older and had more
comorbidity, who appeared to particularly benefit from buprenorphine treatment. This was a novel result
and not specified a priori. Further work is needed to confirm these interactions.
DOI: 10.3310/hsdr07030 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 3
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Steer et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
55
As in other studies, our study also suggested shorter treatment duration for buprenorphine than
methadone treatment, but the intervals between treatments also differed, with buprenorphine having a
shorter off-treatment duration. Overall, current estimates indicate that buprenorphine patients have a
lower percentage time on treatment. There is a clear public health need to retain people on OST longer to
reduce the number of deaths in the population.
Our findings do not advocate prescribing benzodiazepines or z-drugs to OST patients. Gabapentinoids
may also be detrimental, but further replication is needed. Although trends differed by medication, with
benzodiazepine decreasing and gabapentinoids increasing in prevalence during the study period, overall,
for each of these three medications, data since 2002 have suggested that the prevalence of affected patients
remained constant. Our data would suggest that further decreases in co-prescribing would be beneficial.
Our analyses were completed before new clinical guidance on drug treatment was issued.43 This guidance
suggested caution in prescribing OST to patients if there is associated alcohol or benzodiazepine dependence,
or use of other depressant drugs such as pregabalin or gabapentin or some major tranquillisers. Our findings
have shown similar problems in prescribing benzodiazepines, z-drugs or gabapentinoids to patients with an
ongoing opioid disorder irrespective of whether they are on or off OST.
Unfortunately, other critical aspects of OST delivery in CPRD data could not be measured, such as supervised
consumption, availability and intensity of adjunct psychosocial support, and frequency of care-plan assessments
during OST. Further research and alternative methodological approaches are required to measure the intensity
and quality of OST on retention and mortality outcomes. It was found, however, that very few OST episodes
seem to correspond to maintenance therapy, as such a large proportion of OST episodes lasted < 3 months.
Furthermore, only a minority of OST episodes lasting < 3 months had any evidence of tapering of dose indicative
of planned discharge and detoxification. The guidance suggests that ‘duration of maintenance should reflect the
patient’s own preferences and their clinical circumstances (which may include the opportunities available to them
to support their recovery and management of risk)’ (contains public sector information licensed under the Open
Government Licence v3.0).43 It has been shown that, in the majority of episodes, OST is ceased prematurely and
that there is a need to provide additional interventions to retain people on OST to achieve population benefit of
reducing drug-related deaths. Short OST episodes are not unique to primary care, as we show when comparing
average treatment duration between CPRD and a major non-governmental organisation.
Limitations of the study design, data sources and analytic methods
The key limitation of this project was the potential for residual confounding through either imperfectly
measured observed confounders or omitted/unobserved confounders. Several analytic approaches have
been presented to consider the extent of confounding, to aid interpretation of the analyses and to reduce
the bias from such effects. These analyses, such as IPW, tended to strengthen confidence in the results.
There were likely to have been missing prescriptions in the CPRD data. For instance, some patients may have
been treated in specialist drug treatment clinics as well as in primary care. Treatment during periods in prison
are also unlikely to be recorded in primary care. This would lead to not only misclassification of periods on
and off treatment but also possibly misclassification between the first 4 weeks and the remainder of time on
treatment if the missing data had erroneously led to one episode being considered as two. To explore this
further, sensitivity analyses were performed using different criteria for the derivation of episodes, but the
impact on the OST type × period interaction was small. These misclassification of treatment periods would
have also biased mean on- and off-treatment durations. However, it was expected that median durations
would have been less susceptible to any bias.
Periods in prison may also introduce bias and confer additional risks; for example, the period in prison
will be one of lower mortality risk but the period immediately following prison release is of high risk.70
However, prison history was incorporated into the propensity scores as a method of reducing this bias.
CONCLUSIONS
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The small number of DRP deaths among a high-risk group such as OST patients may indicate that these
deaths were under-reported. Although this allowed some conclusions to be drawn relating to the OST
type × period interaction and other interactions with age and comorbidity, other analyses on initiation
and cessation were severely hampered.
Critically, it was not possible to characterise the intensity and quality of OST, and clinical data on addiction
severity or drug use patterns over the 16 years of this study. However, these data are also absent from all
other large-scale drug treatment cohorts. For example, treatment cohorts in New South Wales have fewer
confounders than CPRD and adjusted only for age, gender and treatment history; and NDTMS lacks data on
morbidity and detailed information on type of OST.30,53 There is a clear tension between well-characterised
cohorts or trials of OST and power to detect changes in mortality risk, and it seems unlikely in the immediate
future that refined clinical information can be obtained on large numbers of patients. An alternative
approach, undertaken in the VEdeTTE study,17 is to conduct nested case–control studies within the cohort,
and to collect more detailed clinical information on a smaller number of cases (DRP) and controls (three or
four people with an opioid disorder who at the time of the case were known to be alive) (unpublished
document: Professor Fabrizio Faggiano, University of Eastern Piedmont, and Dr Marina Davoli, Lazio Regional
Health Service Rome 2018).
Since 2007 there have been changes to drug treatment and policy.7,36,71 These include a greater emphasis
on recovery and re-engagement with the community through employment, take-home naloxone to
counteract overdose and a greater diversity of treatment agencies. These factors potentially may confound
our results, particularly the longitudinal trends.
Future research
The results from this project suggest four main areas of future research.
First, replication and strengthening power: the analyses on DRP were limited because only just above half
of the patient episodes were linked to Office for National Statistics data on cause of death. Several of the
analyses involving SCCS methods and for initiation and cessation were underpowered and may provide
clearer evidence if conducted on a larger data set. In addition, novel interactions between age and OST
modality and between comorbidity and OST modality were identified that need to be tested in other data
sets and studies.
Second, cross-cohort comparison: these results relate to UK primary care. There are benefits (in terms
of both replication and identifying potential differences in OST delivery that may increase or decrease
mortality risk) of comparing the CPRD findings with those for cohorts from community drug agencies in
the UK and internationally. This will test whether there are differences between mortality risk in patients
managed in primary care and those managed by community drug agencies, as well as raise hypotheses
on how OST might be better delivered in the UK if differences are found across international cohorts.
Third, intensity of treatment: additional studies are needed both to determine the extent to which OST is
delivered as recommended in current guidelines and to assess whether or not intensity of OST, including
adjunct interventions, protects against DRP during and immediately after treatment cessation compared
with low-intensity/low-threshold OST.
Fourth, interventions: retention in OST is critical to reducing the number of DRP in the population, and
more work with patient groups and clinicians is required on how to deploy buprenorphine and methadone
and other strategies both to reduce mortality risk at the beginning of OST and to retain patients on OST
for prolonged periods to minimise mortality risk long enough to generate public health benefit.
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Data-sharing statement
This study utilised CPRD data that cannot be disseminated further as a result of conditions attached to
their initial release to the authors. These data can be requested directly from CPRD (www.cprd.com).
All queries should be submitted to the corresponding author.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Definition of drug-related deaths
Description ICD-9 codes ICD-10 codes
Mental and behavioural disorders
Attributable to drug use (excluding alcohol and tobacco)a 292, 304, 305.2–305.9 F11–F16, F18–F19
Unspecified cause/disorder F99
Accidental self-harm
Poisoning by drugs, medicaments and biological substancesa E850–E858 X40–X44
Poisoning, other or unspecified exposure E866.8, E866.9 X49
Other or unspecified means E928.8, E928.9 X58, X59.9
Intentional self-harm
Poisoning by drugs, medicaments and biological substancesa E950.0–E950.5 X60–X64
Poisoning, other or unspecified exposure E950.9 X69
Other or unspecified means E958.8, E958.9 X83, X84
Assault by
Poisoning by drugs, medicaments and biological substancesa E962.0 X85
Poisoning, other or unspecified exposure E962.9 X90
Other or unspecified means E968.8, E968.9 Y08, Y09
Self-harm, undetermined intent
Poisoning by drugs, medicaments and biological substancesa E980.0–E980.5 Y10–Y14
Poisoning, other or unspecified exposure E980.9 Y19
Other or unspecified means E988.8, E988.9 Y33, Y34
External cause
Poisoning by drugs, medicaments and biological substances 960–979 T36-T50
Poisoning, other or unspecified exposure 989.89, 989.9 T65.8, T65.9
Other or unspecified cause 995.89 T78.8, T78.9
Ill-defined, unspecified or unknown cause 798.1–798.9, 799.89, 799.9 R68.8, R69, R96–R99
a Office for National Statistics54 (p. 33).
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Appendix 2 Definition of psychosocial adversity
using Clinical Practice Research Datalink medcodes
Self-harm
medcode Description
10057 Deliberate self-harm
10464 Self-harm
17046 [X]Intentional self-harm
22107 [V]Personal history of self-harm
32267 Self-mutilation
35123 Self-mutilation of hands
45796 [X]Sequel intentn self-harm assault+event of undeterm intent
57479 Self-mutilation of genitalia
64200 Self-mutilation of ears
69263 [X]Sequelae of intentional self-harm
Overdose
medcode Description
171 Overdose of drug
1493 Cause of overdose – accidental
6595 Cause of overdose – deliberate
11708 Overdose of biological substance
13568 H/O: repeated overdose
18379 [X]Overdose – paracetamol
28710 [X]Overdose – heroin
29861 [X]Overdose – aspirin
34703 [X]Overdose – amitriptyline
44886 [X]Overdose – ibuprofen
45748 [X]Overdose – diazepam
46280 [X]Overdose – antidepressant
48324 [X]Overdose – benzodiazepine
49552 [X]Overdose – barbiturate
51381 [X]Overdose – temazepam
52931 [X]Overdose – nitrazepam
55395 [X]Overdose – sleeping tabs
60559 [X]Overdose – SSRI
94725 [X]Overdose – amobarbital
99775 Intentional overdose of prescription only medication
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Alcohol problems
medcode Description
1399 Alcohol problem drinking
2081 Alcoholism
2082 Alcohol withdrawal syndrome
2083 Alcohol detoxification
2084 Alcohol dependence syndrome
2925 Alcoholic polyneuropathy
3216 Acute alcoholic hepatitis
4500 Korsakov's alcoholic psychosis
4506 Alcoholic gastritis
4743 Alcoholic cirrhosis of liver
4915 Alcoholic cardiomyopathy
5611 [X]Mental and behavioural disorders due to use of alcohol
5740 Acute alcoholic intoxication in alcoholism
5758 [X]Chronic alcoholism
6169 Alcohol dependence syndrome NOS
6467 [X]Alcoholic hallucinosis
7123 [V]Personal history of alcoholism
7602 Chronic alcoholic hepatitis
7885 Alcoholic liver damage unspecified
7943 Alcoholic hepatitis
8030 [V]Alcohol abuse counselling and surveillance
8363 Oesophageal varices in alcoholic cirrhosis of the liver
8388 [V]Alcohol rehabilitation
8430 H/O: alcoholism
9169 [D]Alcohol blood level excessive
9489 Under care of community alcohol team
9508 [X]Acute alcoholic drunkenness
9849 Referral to community alcohol team
10463 [X]Intent self poison/exposure to alcohol
10691 Alcoholic fatty liver
11106 Korsakov's alcoholic psychosis with peripheral neuritis
11670 [X]Korsakov's psychosis, alcohol induced
11740 Alcohol misuse – enhanced services administration
12353 [X]Mental & behav dis due to use alcohol: psychotic disorder
12554 Referral to community drug and alcohol team
12976 Suspect alcohol abuse – denied
12982 Alcohol intake above recommended sensible limits
16225 Alcohol withdrawal delirium
16237 Alcoholic psychoses
17259 [X]Delirium tremens, alcohol induced
17330 Alcoholic hepatic failure
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medcode Description
17607 [X]Alcoholic psychosis NOS
18156 Alcoholics anonymous
18252 Accidental poisoning by alcohol, NEC
19217 Alcohol causing toxic effect
20514 [X]Mental and behav dis due to use alcohol: withdrawal state
20762 Alcohol amnestic syndrome
21412 Adverse reaction to alcohol deterrents
21624 Episodic acute alcoholic intoxication in alcoholism
21650 Admitted to alcohol detoxification centre
21713 Alcoholic fibrosis and sclerosis of liver
21879 [X]Mental and behav dis due to use of alcohol: harmful use
23978 [X]Evid of alcohol involv determind by level of intoxication
24064 Continuous chronic alcoholism
24485 Chronic alcoholism in remission
24984 Alcohol-induced chronic pancreatitis
25110 Alcohol withdrawal hallucinosis
26106 Episodic chronic alcoholism
26323 [X]Alcoholic dementia NOS
27342 Alcoholic dementia NOS
28780 [X]Alcohol addiction
29691 Aversion therapy – alcoholism
30036 [X]Poisoning/exposure, ? intent, to alcohol
30162 [X]Alcoholic paranoia
30404 Alcoholic paranoia
30460 Alcoholism counselling
30604 Alcohol-induced epilepsy
31443 Chronic alcoholism
31605 [X]Accident poisoning/exposure to alcohol
31742 Alcoholic myopathy
32927 [X]Alcohol withdrawal-induced seizure
33635 Chronic alcoholism NOS
33839 Cerebellar ataxia due to alcoholism
36296 Acute alcoholic intoxication in alcoholism NOS
36499 Alcohol causing toxic effect NOS
36687 Alcohol deterrent poisoning
36748 Alcoholic encephalopathy
37691 [X]Chronic alcoholic brain syndrome
37946 Chronic alcoholic brain syndrome
38061 Alcohol induced hallucinations
39327 [X]Mental and behav dis due to use alcohol: dependence syndr
39799 [X]Mental and behav dis due to use alcohol: amnesic syndrome
40530 Acute alcoholic intoxication, unspecified, in alcoholism
40541 Accidental poisoning by alcoholic beverages
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medcode Description
41638 [X]Int self poison/exposure to alcohol at home
41920 Alcohol amnestic syndrome NOS
41983 Alcohol detoxification
43193 Unspecified chronic alcoholism
44299 [X]Mental & behav dis due to use alcohol: acute intoxication
45169 [X]Men & behav dis due to use alcohol: oth men & behav dis
46677 Alcohol withdrawal regime
47555 Cerebral degeneration due to alcoholism
48241 [X] Adverse reaction to alcohol deterrents
48514 Denatured alcohol causing toxic effect
55415 Accidental poisoning by alcohol NOS
56410 Delivery of rehabilitation for alcohol addiction
56947 Continuous acute alcoholic intoxication in alcoholism
57714 Alcohol dependence with acute alcoholic intoxication
57939 Pathological alcohol intoxication
59414 [X]Intent self poison alcohol unspecif place
59574 Acute alcoholic intoxication in remission, in alcoholism
60752 Accidental poisoning by secondary propyl alcohol
61187 [X]Accid poison/expos to alcohol unspecif place
61190 [X]Pois/expos ?intent to alcohol unspecif place
63306 [X]Accident poison/exposure to alcohol at home
63529 Alcohol misuse – enhanced service completed
63876 [X]Accid poison/expos alcohol in street/highway
64389 [X]Ment & behav dis due use alcohol: unsp ment & behav dis
65754 Alcohol-induced pseudo-Cushing's syndrome
65932 [X]Alcoholic jealousy
67651 Alcoholic psychosis NOS
68159 [X]Poison/exposure ?intent, to alcohol at home
69407 [X]Pois/exp ?intent alcohol school/pub admin area
73876 [X]Alcohol deterrents caus adverse effects in therapeut use
92908 [X]Accid poison/expos alcohol trade/service area
94553 Referral to specialist alcohol treatment service
94670 Alcohol misuse
95181 Alcohol reduction programme
96053 Brief intervention for excessive alcohol consumptn completed
96054 Extended intervention for excessive alcohol consumptn complt
96219 [X]Pois/expos ?intent alcohol in street/highway
96993 Referral to alcohol brief intervention service
103069 [X]Acc poison/expos alcohol school/pub admin area
104611 Alcohol-induced acute pancreatitis
104702 [X]Accid pois/expos alcohol in sport/athletic area
NEC, not elsewhere classified; NOC, not otherwise specified.
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Prison
medcode Description
1123 In prison
10269 Released from prison
21521 Prison record
26013 Prison sentence
28655 [V]Imprisonment
29760 [V]Problems related to release from prison
37738 Imprisonment record
52682 Prison medical examination
53439 [V]Prison medical
54399 Place of occurrence of accident or poisoning, jail
59330 Place of occurrence of accident or poisoning, prison
105175 Medically fit for activity outside prison
Homeless
medcode Description
2562 Homeless
25452 Homeless single person
67112 Homeless – enhanced services administration
96605 Homeless – enhanced service complete
97757 Sofa surfer – person of no fixed abod
104962 Length of time homeless
107393 Under care of homeless advocacy service
DOI: 10.3310/hsdr07030 HEALTH SERVICES AND DELIVERY RESEARCH 2019 VOL. 7 NO. 3
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Steer et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73

Appendix 3 Report on public and patient
involvement
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Appendix 4 Registered patients within Clinical
Practice Research Datalink and the UK by year
Year
CPRD patients by country (0000) Registered patients by country (0000)
England Wales Scotland
Northern
Ireland UK England Wales Scotland
Northern
Ireland UK
1998 236 19 17 8 280 5112 300 536 176 6124
1999 290 25 21 10 346 5090 298 537 177 6102
2000 329 30 24 12 395 5134 301 535 178 6148
2001 359 34 31 14 439 5125 301 535 177 6139
2002 384 35 38 16 473 5152 304 535 178 6168
2003 393 38 48 16 495 5271 302 534 178 6286
2004 403 40 51 17 511 5253 304 537 179 6273
2005 409 41 51 17 518 5282 305 539 179 6305
2006 419 41 52 17 529 5324 309 541 181 6355
2007 422 43 52 17 534 5307 309 542 183 6342
2008 417 44 53 16 529 5361 311 547 185 6404
2009 414 44 53 16 527 5414 313 550 187 6464
2010 413 44 53 16 526 5502 315 552 188 6557
2011 399 44 54 16 513 5531 316 553 190 6589
2012 386 45 54 16 500 5574 317 555 191 6637
2013 379 47 54 16 495 5601 318 557 192 6667
2014 335 46 55 16 451 5647 317 560 194 6718
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